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Herpes simplex viruses (HSV) infection is a common cause of ocular disease 
and can result in a chronic inflammatory reaction that impairs vision. This 
latter manifestation is called herpetic stromal keratitis (HSK) and usually 
occurs as a consequence of virus reactivation from latency in the trigeminal 
ganglion. The pathogenesis process involves complex interactions of cellular 
and molecular events. HSK in humans, and certainly its murine experimental 
model, appears to be an immunopathologic disease process. The crucial cell 
type orchestrating the inflammation is a CD4+ Tcell that has a Thl cytokine­
producing profile. However, prior to this immunoinflammatory phase, 
multiple events occur that set the stage for subsequent pathology. These 
include production of cytokines and chemokines, infiltration of innate immune 
cells and neovascularization of the avascular cornea. 
Current understanding about human and murine HSK pathogenesis is 
reviewed in Part I. Part II progresses this knowledge using knockout and 
transgenic mice. Results in Part II clarify the essential role of IL-l, a 
proinflammtory cytokine, produced as a consequence of virus replication, in 
HSK pathogenesis. Part III, in addition to Part II, elucidate the mechanisms 
involved in IL-l and IL-6 mediated polymorphonuclear leukocyte (PMN) 
influx and neovascularization of cornea following virus infection. These 
cytokines were shown to be produced quite early after infection and capable of 
inducing angiogenic factors, resulting in angiogenesis of the cornea. In 
addition, the role of IL-l in inducing proinflammatory arachidonic acid 
metabolites has been discussed in PART IV. Cycloxygenase 2 enzyme 
iv 
produced from resident corneal cells in presence of IL-l was shown to be 
crucial for creating an inflammatory milieu and facilitate early PMN influx in 
murine cornea. These results provide novel insights into the link between viral 
infections, pro-inflammatory mediators, PMN migration, angiogenesis and 
HSK development. Our understanding about the role of IL-l in HSK 
pathogenesis was evaluated clinically in Part V using an IL-l receptor 
antagonist (IL-l ra) protein. Mice receiving IL-l ra h~d diminished disease 
severity. The administration of IL-l ra was shown to reduce the influx into the 
cornea of cells of both the innate and adaptive immune response. In addition, 
the treatment also diminished corneal VEGF levels resulting reduced 
angiogenic response. Our results show the iluportance of targeting early 
proinflammatory molecules such as IL-l to counteract HSK and advocate IL-l 
ra as an effective agent to achieve this. In Part VI, a novel flow cytometry 
based assay has been used to quantify corneal angiogenesis following ocular 
HSV infection. Our results indicate that, this assay was sensitive enough to 
able to pick up the difference in angiogenic response between mice. Thus, 
estimation of angiogenesis on the basis of number of endothelial cells proved 
to be a useful approach to quantify corneal neovascularization. 
This dissertation presents research aimed at elucidating both molecular 
and cellular events in HSK pathogenesis. These results will serve as guidelines 
for future development of more efficient prophylactic and therapeutic 
strategies. 
v 
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Information provided in this chapter is a slightly modified version of a review 
article accepted for publication in the Microbes and Infection published by t 
Partha Sarathi Biswas and Barry T. Rouse. I 
,
Biswas, P. S., and B. T. Rouse. Early events in SK pathogenesis- setting the 
stage for a blinding disease. Microb. Infection. In press. I 
IMy contributions in this review include (1) selection of the topic (2) 
fcompilation of information data analysis and interpretation (3) plan review 
outline (4) writing (5) preparation of figures and manuscript editing. 
INTRODUCTION 
On the basis of the fact that 80% or more of the adult human populations may 
be sero-positive for herpes simplex virus (HSV), this virus must be judged as a 
highly successful pathogen. Furthermore, the virus kills very few patients and 
most who suffer lesions recover without significant conlplications. However, 
when the eye becomes the site of infection, a chronic immuno-inflammatory 
syndrome may result that impairs vision (1). Such herpetic stromal keratitis 
(SK) lesions represent the commonest infectious cause of blindness in the 
western world. It is estimated that in USA, 400,000 persons are affected, with 
20,000 new cases of SK occur annually; the incidences ranges from 4.1- 20.7 
cases/100,OOO patient years (2). In humans, SK is usually the sequel to 
recurrent infection following reactivation of virus from the trigeminal 
ganglion (1). The pathogenesis of human SK is considered to involve T cell 
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mediated inflammatory events, a notion strongly supported by experimental 
studies in a mouse model (1, 3, 4, 5). In this model, the lesions are mainly 
orchestrated by CD4+ T cells (4, 5) although the identities of target antigens 
that drive such cells remain ill-defined. In addition, several events occur in the 
infected eye prior to the onset of clinically evident SK. Since such events may 
be subject to manipulation and the control of lesion severity, understanding 
early events represents an important objective for SK research. This review 
describes recent work from our laboratory and others, which defines multiple 
pathogenic mechanisms ongoing during the early phase of SK in the mouse 
model. We also comment about what is understood about the clinical phase of 
SK. 
VIRUS ENTRY IN THE CORNEA 
Following primary infection, herpes viruses reaching the surface of the eye are 
initially suspended in the ocular tear film. The key feature of ocular surface 
innate resistance is the constant bathing of the ocular surface by tears 
produced from the lachrymal gland. Thus molecules, cells and infectious 
agents reaching the ocular surface may be washed away quickly and 
effectively. In addition, virus infections are vulnerable to a number of 
substances with antiviral activity present in tears. These include lysozyme, 
immunoglobulin A antibody, complement, lactate dehydrogenase, amylase 
and peroxidase. Interferons, particularly alpha and beta types also occur in 
tears during a viral infection of the ocular surface (6- 9). The intact corneal 
epithelial cell layer may act as an effective physical barrier to infection by 
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microorganisms, and its outer terminally differentiated cells may be refractory 
to infection, such as by HSV (10). However, whereas this broad spectrum of 
defenses limits the chance of infection, agents such as HSV do establish 
infection usually in the epithelial layer of the cornea (11). 
Successful infection by HSV induces several key events that relate to 
the subsequent development of ocular pathology. One such event, which in 
fact does not require progeny virus production, is entrance into sensory nerve 
terminals in the corneal epithelium. Virus then travels by retrograde transport 
to the neuronal cell bodies in the trigeminal ganglia (TO) (12, 13). Using a 
LACz encoding virus, Hill and colleagues demonstrated that, virus can reach 
the TO within 24 hrs of ocular infection irrespective of the viral dose used 
(14). In the TO, virus either replicates usually killing cells, or enters into an 
alternative replication mode called latency which may persist in cells 
indefinitely (13, 15, 16). It is also conceivable that viruses may undergo a 
productive cycle but this is contained in some way 'by signals from immune 
cells, primarily CD8+ T cells (17, 18), [19]). While the latent state, which may 
involve 100 more copies of the viral genome, may be permanent in many 
cells, in others it is terminated in response to a variety of stimuli (15, 16). 
When this occurs virus reenters into the productive cycle, and progeny virus 
passes anterograde along nerve exons to produce a recurrent bout of virus 
replication at the initial site of infection (13, 15). Such recurrences may be 
subclinical or clinical and in the eye may either give rise to secondary lesions 
in the epithelium or cause a chronic inflanlmatory reaction in the underlying 
stroma. 
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The stromal inflammatory reaction occurs in around 20% of human 
cases and this is the lesion that is mainly responsible for vision impairment 
(2). The lesion is judged to largely represent a T cell mediated immuno­
inflammatory event, but details of the pathogenesis are poorly understood (3, 
4). Thus it is not clear if virus itself enters the stroma and if so whether this 
spreads from the infected epithelial site or arrives via axonal passage from the 
TO. Moreover, although T cells form a prominent part of the stromal 
response, the nature of target antigens that are being recognized remain to be 
identified. Most of our understanding of the pathogenesis of SK comes from 
experimental studies in the mouse where the lesions regularly occur as a 
sequel to primary infection. Shnilar lesions can occur by induced reactivation 
(20), but this perhaps more relevant model, is difficult to establish and occurs 
in only a minority of animals. Our description of events in the stroma that 
result in the chronic blinding immuno-inflammation applies to the primary 
disease model and when known the natural human disease. 
VIRUS AND EARLY INFLAMMATORY EVENTS 
Inflammatory cells 
Following virus infection of the corneal epithelium, a prominent infiltrate of 
inflammatory cells, primarily consisting of neutrophils (PMN) (21), occur into 
stromal tissues subjacent to the infected epithelium (See Fig 1) (Note all figure 
in appendix). The cells escape from the limbal vessels presumably in response 
to signaling molecules generated from virus infected cells. This response starts 





that by 5 days after infection it is barely evident (21). This pattern of events 
correlates with the duration of virus detection and it seems that PMN may be 
responsible for viral clearance (21, 22). Thus depleting PMN with specific 
monoclonal antibodies resulted in delayed viral clearance from the cornea. It is 
not clear how virus, which is predominantly in the epithelium, is cleared by 
the mainly stromally located PMN. Ideas for the mediation of such defenses 
include TNF-a, nitric oxide and reactive oxygen metabolites production by 
PMN. Evidence for this comes from studies where corneal neutrophils were 
shown to produce these factors by in situ hybridization techniques (23). 
The stromal PMN response may have other consequences. For 
example, factors released following PMN degranulation resulted in tissue 
destruction which may unmask corneal autoantigens. One of these factors is 
NO (24). Polymorphonuclear leukocytes as well other cells in the early 
response, also contribute to the ongoing inflammatory process by producing 
proinflammatory cytokines such as IL-1~, TNF-a, IL-8 and IL-12 (23), thus 
setting the stage for the subsequent chronic immunoinflammatory phase. 
Crucial components of PMN include a source of preformed VEGF (25), as 
well as the tissue degrading enzyme matrix metalloproteinase-9 (MMP-9) 
required to breakdown the stromal matrix (26). Both molecules are involved in 
the neovascularization which results from HSV infection (discussed later) (26, 
27) (See Fig 2). 
Although PMN dominate the early inflammatory phase, other cell 
types can also be demonstrated in the stroma. These include macrophages 
(28), dendritic cells (DC) (29, 30), natural killer cells (NK cells) (31, 32) and 
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yo T cells (33). NK cells and macrophages likely also participate in corneal 
virus clearance and can also act as a source of cytokines, chemokines and 
angiogenic factors (28, 31, 32). In line with this notion, depletion of NK cells 
and macrophages following ocular HSV -1 infection resulted in more severe 
SK (28, 31, 32). Another prominent feature of the injured cornea, including 
that caused by HSV, is the invasion of Langerhans DC, likely from the 
conjunctiva, into the cornea (29, 30). However this event takes several days to 
occur. Presumably, such cells also act as a source of cytokines and 
chemokines but their major function in SK pathogenesis is probably to 
transport viral antigens to lymphoid tissues where the adaptive immune 
response is initiated (discussed later). However, recent findings by Carbone 
group question the role of Langerhans cells for antigen presentation. They 
contend that such cells pass on viral proteins to other subsets of DC which 
process Ag by cross priming and present antigen to CD8+ T cells (34). At 
present the respective roles of these numerous nonlymphoid inflammatory 
cells in the early response to HSV remains unresolved. Thus past observations 
have focused on a single cell type and usually ignored the role of others. One 
suspects that a large measure of cell to cell interaction could be occurring. 
This could include regulatory effects mediated by natural regulators such as 
NKT cells. Such effects have been noted to occur in the anterior chamber (35), 






HSV infection of the cornea causes the expression of multiple proteins 
associated with the inflammatory response. Among the numerous cytokines 
that are produced IL-1 and IL-6 are prominent and these may be pivotal in 
starting the cascade of events that results after several days in stromal lesions 
(36, 37). When HSV productively infects a cell, most host gene expression is 
turned off (38). Nevertheless infected cells are stimulated to produce IL-1 and 
IL-6 at least for a time and this may represent their major initial source (39­
41). However, it is evident that uninfected cells ultimately become the major 
cell source of cytokines. It is not clear how the uninfected cells are induced to 
produce cytokines but one viable idea is that pathogen associated molecular 
patterns (PAMPS) expressed by virus infected cells, or perhaps extracellular 
virus itself, could bind to Toll-like receptors (lLR) on cells and cause them to 
synthesize and secrete cytokines and other inflammatory mediators. With 
respect to HSV, there is evidence that the viral DNA may have lLR-9 
stimulating activity (42) although there may be insufficient extracellular viral 
DNA present in vivo to subserve that function. Furthermore, recently HSV 
was proposed to have lLR-2 binding activity although the viral components 
responsible for this await identification. At least in the central nervous system 
(eNS), it seems that HSV, via its lLR-2 activating property, may cause IL-6 
production as well as other mediators (43). We are investigating this issue in 
the cornea where we anticipate that lLR-2 binding may be a critical stimulus 
for IL-l production. 
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Whereas PAMPS may be important for initiating the inflammatory 
protein cascade, it also seems likely that the initial cytokines induced are also 
involved in driving the expression of other key molecules. Thus IL-I can 
cause IL-6 production from uninfected epithelial cells (44), and IL-6 is known 
to induce macrophage inflammatory protein-2 (MIP-2) (CXCL8), likely a key 
molecule for PMN recruitment in the stroma (45, 46). This issue has been 
extensively studied by us and others using IL-6-/- mice (46), CXCR2-/- mice 
(47) and neutralization of MIP-2 using specific monoclonal antibody (45). In 
all these studies PMN ingress to the corneal stroma was shown to be severely 
compromised (45-47). In addition, IL-I was also shown to influence PMN 
migration and via its stimulation of IL-6 expression (44). In line with this 
observation, mice transgenic for the IL-I receptor antagonist protein showed a 
diminished early inflammatory response (48). 
In addition to IL-6, another factor known to be upregulated in corneal 
stromal cells following IL-I stimulation is Cycloxygenase-2 (COX-2) (our 
unpublished data). COX-2 induced proinflammatory prostanoid synthesis such 
as prostaglandin E2 (PGE2) can cause PMN invasion in various inflammatory 
models (49). Corneal fibroblasts may act as a major cellular source of COX-2 
(our unpublished data). Possible agonists that drive COX-2 production at an 
early time point include proinflammatory cytokines such as IL-1 ~ and TNF-a 
(our unpublished data). Thus blocking COX-2 activity at an early time point 
with a specific COX-2 inhibitor diminished PMN influx and resulted in less 
SK severity (our unpublished data). Another cytokine known to be 
upregulated following ocular HSV infection is TNF-a (50, 51). Recent studies 
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have demonstrated that TNF-a-I- mice were more susceptible to acute corneal 
HSV-1 infection than controls, as manifested by an increased ocular virus 
titers and mortality rate (51). 
Another early cytokine event that may be pivotal in the pathogenesis of 
SK is IL-12. Our group was the first to demonstrate that a viral infection may 
cause IL-12 production (52). Using a sensitive radioimmunoassay, IL-12 
transcripts were detected in HSV infected corneas as early as 1 day p. i., with 
peak levels around day 3 p. i. and sustained production until at least day 22 p. 
i. (52, 53). That IL-12 production is an important event was best shown by the 
observation that both p35-1- and p40-1- mice develop only mild lesions of HSK 
(54). However, it is still unclear how HSV infection induces IL-12 production. 
The best evidence is that the event is largely a paracrine one (53) but the 
identity of the stimulus for IL-12 production by uninfected cells remains to be 
identified. Possible mediators under consideration include cytokines, 
chemokines, stress proteins, and viral products released from infected cells. 
With regard to the latter, virions themselves would seem to be unlikely 
candidates, as UV -inactivated virus and fixed cells expressing viral proteins 
caused only minimal IL-12 induction (53). Another candidate could be viral 
DNA, a source of DNA rich in potentially bioactive CpO motifs known to be 
potent IL-12 inducers (55), but such issues await confirmation. The 
inflammatory cells such as PMN and macrophages, but not corneal resident 
cells, are the likely source of IL-12 following viral infection (23, 53). 
The cytokine IL-12 has several downstream effects that have impact 
on SK pathogenesis. These include production of IFN-y by cells with IL-12 
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receptors. Although not proven in eye, the most likely cells that respond and 
produce IFN-y are NK cells, macrophages and neutrophils. Removal of each 
cell type may compromise the ability to clear virus from the cornea and CNS 
(22, 28, 31). Furthermore, IL-12 transgenic mice clear virus quickly by 
upregulating IFN-y production in the cornea (56, 57). Previous observations 
suggest the role of STAT 4 dependent pathway in the production of IFN-y 
following IL-12 stimulation (57). Supporting this scheme we were able to 
demonstrate that STAT4-/- mice have lower levels of IFN-y in the cornea 
following virus infection (our unpublished data). Whatever the source of IFN­
y is, this molecule appears to be pivotal in antigen processing as well as other 
events in HSK pathogenesis. These include aiding PMN influx in the corneal 
stroma by up-regulating PECAM-l (Platelet endotholelial cell adhesion 
molecule-I) expression on vascular endothelial cells (9). Conceivably, 
neutralization of PECAM-l or IFN-y resulted in diminished PMN ingress (9). 
In addition, in vitro stimulation of human corneal epithelial cells with IFN- y 
caused upregulation of ICAM-l expression, another cell adhesion molecule 
responsible for adhesion and extravasation of inflammatory cells (58). IFN- y 
also upregulates MHC II expression on antigen presenting cells (APC) 
involved in the induction of antigen specific CD4 + T cells in the draining 
lymph nodes (59). Interestingly, murine stromal fibroblasts can express MHC 
II and present antigen following stimulation with IFN- y (60). On the other 
hand, IFN- y could help modulate lesion development since it also induces 
angiostatic chemokines such as IP-I0 (CXCLI0) (61). Thus, IL-12 and IFN- y 
11 

response to HSV infection indirectly impacts on both inflammatory and 
regulatory effects during SK. 
Another cytokine that deserves attention in SK pathogenesis is IL-I7. 
Recent work by the Verjans group has demonstrated the presence of IL-I7 and 
its role in PMN influx in human SK (62). In this report, IL-I7 was shown to 
influence PMN infiltration through upregulation of IL-6 and IL-8 (62). In 
addition IL-I7 might stimulate VEGF production and aid in the angiogenesis 
process (63) (discussed later). However, the cellular source as well as the 
stimulus of IL-I7 in infected corneas remains ill-defined. One possibility is 
IL-23, which is well known to induce IL-I7 from a variety of cell types in 
various inflammatory models (64)~ Usually IL-23 acts to induce IL-I7 in 
lymphocytes, which in the HSV infected cornea, do not enter the cornea until 
6-7 days p. i. (64). However since IL-23 and IL-I7 producing CD4+ T cells 
were shown to be crucial events in some other chronic inflammatory 
conditions, their role in various stages of herpetic keratitis merits further 
investigation. 
Much remains to be established with regard to cytokine expression and 
function during the early phase of ocular infection with HSV. One crucial step 
for the pathogenesis of SK that is initiated early after infection is 
neovascularization of the normally avascular cornea. As is discussed later, 
several cytokines may participate in the angiogenesis process by acting as 
stimulants for the induction of angiogenesis factors; some cytokines, however, 





Following viral replication in the epithelial layer, several chemokine mRNAs 
are promptly upregulated in the cornea (65, 66). The fact that viral replication 
for an initial few days is essential has been established by showing feeble 
chemokine responses if virus was neutralized with antibodies (65) or corneas 
were infected with UV inactivated or replication incompetant mutant virus 
(67). The cellular source of chemokine and the nature of the induction stimuli 
remain ill-defined. Cells infected by the virus are the most logical candidate 
source, but once virus replication is well underway in a cell, host cell mRNA 
is curtailed (38). Some evidence does exist however, that the viral immediate 
early protein ICPO is all that is necessary to induce chemokines expression 
(67). An alternate cellular source is the nearby corneal resident cells as well as 
inflammatory cells that are exposed to products from HSV infected cells. This 
issue of cellular source of various chemokines in HSV infected eye must await 
the refinement of approaches such as in situ hybridization and double color 
ilnmunohistochemistry to study this topic. 
Early after HSV infection CXC chemokines such as MIP-2 and KC 
(CXCL3) were shown to predominate (65, 67). In addition MCP-1 (CCL2), 
RANTES (CCL5), IP-10 (CXCL10) was also present (65). Recently one group 
demonstrated that corneal epithelial cells and stromal keratocytes express 
MIP-3a (CCL20) mRNA and protein following ocular HSV -1 infection (68). 
Despite the representations of multiple chemokine during early HSV infection, 
some studies do indicate that single chemokines may be crucial for SK 
pathogenesis. Thus the Lausch group demonstrated that neutralization of the 
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CXC chemokine MIP-2 markedly suppressed the initial PMN influx (45). 
Even more significant suppression was obtained when both K-C and MIP-2 
were neutralized together (45). These observations were in fact supported by 
our own finding using CXCR2-/- mice. These mice demonstrated 
significantly reduced PMN invasion at an early time point (47). However, the 
induction stimulus for these chemokines seemed to be proinflammatory 
cytokines produced as a consequence of virus replication in the corneal 
epithelium. We also know that IL-6 promotes MIP-2 production from resident 
cells in an autocrine- paracrine manner (44). In addition, corneal epithelial 
cells and stromal cells produce CCL20 following stimulation with IL-l ~ and 
TNF-a (68). It will be important to determine what functions chemokines such 
as these are playing during the early phase. One possibility is that they serve to 
attract inflammatory cells that in turn also act as a source of chemokines. 
An additional group of chemokines that lacks expression during the 
early inflammatory phase but are expressed during late preclinical phase are 
MIP-1 a (CCL3) and lymphotactin (XCL1) (67). What causes upregulation of 
these is not known, but they are likely responsible for CD4+ T cells influx 
during the clinical phase. Supporting this notion Lausch and his colleagues 
demonstrated that MIP-1 a-/- mice fail to show the secondary inflammatory 
cell influx and do not develop SK (69). In addition, neutralization of MIP-1a, 
or the application of 1L-10 which abrogates MIP-1 a production, resulted in 
diminished SK severity (70). However mechanistic explanations for these 
observations have not been provided. Another unresolved issue in SK 
pathogenesis includes an explanation for the markedly preferential invasion by 
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CD4+ T cells versus CD8+ T cells to the infected cornea. This issue is 
currently under investigation in our laboratory (discussed later). 
VIRUS AND ANGIOGENESIS 
One characteristic of HSV induced immunopathology is neovascularization of 
the cornea, an event shown necessary for SK pathogenesis (27). Whereas the 
normal cornea is avascular, in SK new blood vessels sprout from limbal 
vessels by day 1 p. i. reaching the central cornea by day 20 p. i. (71). 
Inflammatory cells readily escape from these highly permeable neovessels, 
giving rise to haze and vision impairment. Indeed neovascularization 
anywhere along the visual axis may impair vision, with vessel removal being 
highly problematic. 
Although the cornea has been a favorite tissue to study angiogenesis, 
the identity of specific angiogenic factors involved in corneal 
neovascularization associated with HSV replication remains in its infancy. 
Curiously HSV replication in the epithelium results in angiogenesis in the 
underlying stroma. Furthermore unlike some other viruses, most notably 
human herpes virus 8 (72-75) and Orf virus (76), HSV appears not to encode 
proteins which are themselves directly angiogenic. In consequence, the means 
by which HSV infection results in angiogenesis likely involves a cascade of 
cytokine mediated or other paracrine events. These events in tum are assumed 
to cause expression of one or more proteins directly involved in angiogenesis. 
Our group has gathered support for these ideas. We have shown, for example, 
that HSV infection is followed by the expression of several known 
15 

angiogenesis factors in the cornea. These include Vascular endothelial growth 
factor (VEGF) (71), basic Fibroblast growth factor (bFGF) (our unpublished 
data), Matrix metalloproteinase 9 (MMP-9) (26) and E-L-R motif containing I 
chemokines (47, 65, 67). 
In SK, VEGF mediated angiogenesis is a prominent and early feature I 
of the pathogenesis, with VEGF transcripts detectable by 12 hr p. i. and t 
proteins by 24 hr p. i. (71). Such observations imply a role for VEGF in HSV t 
induced angiogenesis; a notion supported by the fact that treatment of mice t 
with a VEGF inhibitor resulted in reduced HSV induced angiogenesis (71). In t 
addition, turning off VEGF and VEGF receptor 2 gene expressions using t 
small interfering RNA (siRNA) resulted in diminished angiogenic responses 
following virus infection (77). In consequence, these mice demonstrated less 
severe SK (77). While looking for the cellular source of VEGF initially after 
infection, uninfected corneal epithelial cells and stromal cells were shown to 
be involved (71). However, with the infiltration of inflammatory cells, such as 
PMN and macrophages, these cells act as an additional and perhaps the major 
source of VEGF (71). Interestingly, the production of VEGF appeared to be a 
paracrine effect of molecules released from virus infected cells, since 
uninfected corneal cells and not infected cells stained positive for VEGF. As 
seen in corneal tissue sections, the VEGF producing cells were close to 
infected cells but were seldom infected themselves (71). 
The above observations raise the question as to the mechanisms by 
which HSV infection of a cell triggers another cell to tum on VEGF gene 
expression. Although productive HSV infection, by virtue of its virion host 
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shut-off protein, eliminates most host cell protein synthesis (38), evidence 
suggests that some proinflammtory cytokine genes such as IL-l and IL-6 are 
upregulated for a time in infected cells «39-41). These cytokines are known to 
be potent stimulators of VEGF production (78-81). In addition, intrastromal 
injection of IL-l and IL-6 results in corneal neovascularization in a VEGF 
dependent manner, since neutralizing VEGF with a monoclonal antibody 
resulted in a significant reduction in the angiogenesis process (44, 47). 
Supporting this scheme, we could demonstrate that blocking IL-l with an IL-l 
receptor antagonist protein resulted in compromised angiogenesis following 
ocular HSV infection (48). 
An additional paracrine stimulus for VEGF production may be HSV 
DNA, rich in bio-active CpG motifs. Our group was the first to demonstrate 
that bioactive CpG motifs can induce corneal angiogenesis by upregulating 
VEGF, indicating an essential role for TLR-9 mediated signaling events (82). 
However, the exact mechanism of VEGF upregulation is not fully understood. 
One possibility is HSV CpG TLR 9 interaction induces a signal transduction 
mechanism that proceeds through a MyD88 dependent or independent 
pathway to activate various transcription factors such as NFk{3. An alternative 
idea to explain this issue is that bioactive CpG ODN induces the production of 
cytokines such as IL-l and IL-6, which in tum upregulate VEGF production. 
Such notions await confirmation. 
Since certain chemokines with E-L-R motifs are well known to have 
angiogenic activity (83), these also represent likely candidates for induction of 
ocular angiogenesis. One such chemokine known to be upregulated following 
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ocular HSV infection is MIP-2 (47, 65, 70). Curiously, other chemokines such 
as some CXC chemokines lacking the E-L-R motif, may inhibit angiogenesis 
(84). Some of the angiostatic chemokines exert their function by binding to 
heparan sulphate on target cells (85). Interestingly, heparan sulphate is also a 
molecule involved in HSV entry into target cells (86). Thus, it is conceivable 
that HSV may bind heparan sulphate and block the angiostatic activity thus 
driving the process towards angiogenesis. These issues are currently under 
investigation in our lab. 
Another molecular species involved in HSV induced angiogenesis was 
the collagenase MMP-9, an enzyme that degrades the stromal matrix material. 
MMP-9 has been associated with tumor angiogenesis (87, 88), but the first 
evidence that MMP-9 contributes to corneal angiogenesis came from our 
laboratory (26). The cellular source of MMP-9 was shown to be PMN, since 
depletion of cells resulted in diminished MMP-9 levels in corneal extracts ,

(26). It appears that targeting MMP-9 production with for example siRNA can 
result in diminished corneal angiogenesis (89). In addition to PMN, corneal 
epithelial cells may produce MMP-9 in response to inflammatory cytokines I 

such as IL-l and TNFa (90). 
While the majority of the proinflammatory cytokines are indirectly I 

I
involved in the corneal angiogenesis process, evidence accumulates to indicate 
that some cytokines such as IL-12 (61) and IL-18 (our unpublished data) t 
inhibit corneal angiogenesis by downregulating VEGF expression. Thus I 

overexpression of these cytokines in the cornea following virus infection I 
resulted in diminished angiogenesis and less severe HSK (Lee et ai, 2002a) 
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(61). It seemed that IL-12 and IL-IS through their inhibitory effect act as 
negative regulators and keep the neovascularization process under a tight 
control following virus infection. 
As is well known in both the fields of ocular pathology and cancer 
biology, it is easier to prevent angiogenesis than removing already established 
blood vessels. Thus early targeting of the angiogenesis process is essential 
because inhibition of neovascularization has no benefit in terms of HSK 
lesions if the vascular bed has already developed (71). To achieve a 
satisfactory level of angiogenesis inhibition, currently the best bet might be to 
use a combination of approaches and a variety of angiogenic molecules need 
to be targeted. These include direct inhibition of VEGF and MMP-9 using a 
combination of the VEGF antagonist (mFlt-immunoglobulinG) (71) and the 
Tissue inhibitor of metallo proteinase 1 (TIMP-l) (26) or indirectly control 
angiogenesis by limiting inflammation using anti-inflammatory drugs such as 
the IL-l receptor antagonist protein (4S) and COX-2 inhibitors (our 
unpublished data). A promising new candidate for therapeutic applications is 
the recently used siRNA targeted against various angiogenic factors in the 
cornea (77). However a major constraint in all these approaches includes the 
lack of effective corneal delivery systems. So far, practical methods to achieve 
efficient corneal delivery of antiangiogenic molecules are not on hand, but 




STROMAL KERATITIS - THE OUTCOME OF INFECTION 

Following the early events described previously which usually include the 
cessation of viral replication and the removal of readily demonstrable viral 
antigens from the eye, lymphocytes and other inflammatory cells invade the 
stroma producing clinically evident SK. This process usually begins 6-9 days 
p. i. and the cellular responses are at their peak around 2-3 week p. i (91). Few 
studies have followed lesions for long periods to note subsequent changes in 
the inflammatory response. However observations on human lesions indicate' 
that they usually fail to resolve spontaneously, and require prolonged 
treatment with anti-inflammatory drugs (11, 92). The pathogenesis of SK 
provides us with several unresolved questions. Among the most difficult to t 
explain is what drives the inflammatory reaction after the virus infection itself t , 
appears to have been contained. Moreover, it is difficult, if not impossible, to 
generate SK either with inactivated viral preparations or indeed with I 
nonvirulent mutant viruses (93). In our hands, replication by wild type viruses I 
tis necessary for at least 2 days to induce SK (94). Furthermore, so far we have 
been unable to cause SK by introducing antigen into the corneal stroma of 1 
animals with adoptively transferred antigen reactive T cells. I 
IIt seems that replicating virus is necessary to drive the array of early 
1events described previously which are essential for SK development. 
1However, neither replicating virus, nor as far as we can measure, persistent 
viral antigen in the cornea, is involved in driving the chronic immuno­
inflammatory phase (93). Presumably, early events leave the corneal stroma in 
a condition that attracts inflammatory cells with these recruits perhaps further 
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activated to participate in tissue damage. We know that one step necessary for 
this event to occur is neovascularization, driven by VEOF and other 
angiogenesis factors (26, 27, 71). Moreover, new blood vessels induced by 
VEOF are quite permeable and readily leak vascular contents. In the stroma, 
this leakiness cannot be random, since the majority of inflammatory cells in 
the site express homing molecules such as the integrin VLA-4 (95). In 
addition, in mouse SK lesions, inflammatory CD4 + T lymphocytes outnumber 
CD8+ T cells (96). This observation cannot be explained by a failure of the 
HSV infection to activate a CD8+ T cell population. In fact, at least in the 
C57BL6 mouse, HSV infection activates a higher frequency of CD8+ than 
CD4+ T cells, yet even in such mice demonstrating CD8+ T cells in SK lesions 
are problematic (96). Furthermore, even adoptive transfers of transgenic CD8+ 
T cells that recognize viral antigen are difficult to demonstrate in the corneal 
lesions (96). Curiously, viral specific CD8+ T cells are readily demonstrable in 
other inflammatory reactions caused by HSV such as in the TO (97). Reasons 
why CD8+ T cells sparsely infiltrate stromal lesions need to be found. 
With regard to the CD4+ population that forms part of the SK lesions, 
the spectrum of antigens such cells recognize remains unknown. We anticipate 
that viral antigens are the targets for some CD4+ T cells especially early during 
the reaction, although this point has not been confirmed. What is known is that 
CD4+ T cells are needed to generate lesions (98, 99). Furthermore, the 
inflammatory function of CD4 + T cells can be modulated by other subsets of 
CD4+ T cells that exert regulatory function (95). This seemingly IL-10 
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producing function is assumed to be viral antigen specific, but this issue has 
also not been firmly established. 
Clearly the role of viral antigen in driving specific CD4+ T cells in 
stromal lesions requires further study. In fact using TCR transgenic mice on a 
SCID or RAG background that were unable to recognize viral antigens, SK 
could be induced in these mice although as in immunocompetent animals, this 
only occurred following infection with replication competent virus (100, 101). 
In these TCR transgenic models, even administrating the cognate antigen into 
the cornea failed to induce SK. Hence in this model too, we are left with the 
dilemma of explaining why it is necessary to administer infectious virus in 
order to generate SK lesions. Conceivably, the T cells involved may recognize 
a wide range of antigens which could include autoantigens unmasked in the 
cornea by the inflammatory response. 
One favored explanation to explain the pathogenesis of SK is that the 
lesions may be initiated by viral damage but subsequently they become 
autoinflammatory (102) (See Fig 3). This concept explains that the virus 
replication some how unmasks autoantigens in the eye and additionally 
stimulates an antiviral T cell response that is cross-reactive with the corneal 
autoantigens. The best evidence for this notion comes from the Cantor 
laboratory, which maintains that the UL6 protein of HSV acts as a molecular 
mimic for a corneal auto-peptide (103). This provocative hypothesis has not 
been independently confinned and our laboratory and others have raised 
questions about the interpretation (104). Indeed molecular mimicry as an 
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explanation for an association between virus and any autoimmune disease has 
been difficult to prove. 
If molecular mimicry is not an explanation for SK pathogenesis, 
conceivably some form of sustained bystander activation of T cells could be 
involved. However currently this intriguing notion lacks a mechanistic 
explanation of where and how such bystander activation takes place. One 
possibility is that inflammatory molecules produced as a consequence of 
ocular HSV infection activate the T cells in a non TCR mediated manner (See 
Fig 4A). This idea is supported by the observation that it is possible to develop 
lesions identical to HSK in animals whose T cells are genetically incapable of 
recognizing viral antigens (94, 105). In these models, the chronic source of 
activating cytokines was cells dying of HSV infection. In this instance, virus 
persisted and spread to the stromal tissue location in some way (94, 101). We 
have hypothesized that, this continually replicating virus in the corneal stroma 
acts, possibly by TLR ligand activity, as the chronic stimulus for cytokine 
Ichemokine production that in tum activates the incoming T cells. Such cells 
then produce inflammatory mediators which participate in tissue damage. 
The conclusion is that the stromal viral persistence is necessary, but the 
mechanistic explanation for the source of virus is controversial. The 
possibilities include direct cell-to-cell spread from corneal epithelium to 
stroma or virus reactivation from the TO. Previous work from our group using 
a thymidine kinase knock out (tk-I-) virus (virus unable to reactivate in TO) 
demonstrated that viral antigens were undetectable in the corneal stroma and 




in the corneal stroma is from the TO, an interpretation further supported using 
an Us9-/- mutant virus that retains normal peripheral virulence but fails to 
transport anterograde after any reactivation (personal communication with Dr, 
David Johnson, Oregon Health Centre). We observed that irrespective of the 
dose used, Us9-/- virus failed to arrive in the corneal stroma and the mice had 
diminished, although not absent SK lesions (our unpublished data). These 
results support a mechanistic role for stromal virus in the bystander model but 
do not reveal how such virus contributes to the inflammatory effect. We are 
currently evaluating the role of a number of candidate mechanisms. These 
include the PAMP effect, superantigen expression and inflammatory reactions 
driven by stress proteins 
In immunocompetent animals, it could be that HSV induces SK 
indirectly in a "hit and run" fashion. Thus virus replication might only serve to 
set off an inflammatory and angiogenic response that becomes sustained 
without the further participation of virus. Should this be the case, then HSV 
induced immunopathological lesion differs from most viral 
immunopathologies since viral persistence is the normal circumstance. Our 
view is that HSV replication is required to marshal a complex of events, which 
we term the "alarm complex". This collage of molecules serves directly or 
indirectly to signal the ingress and subsequent activation of neutrophils and 
DCs in the stroma and angiogenic sprouting from the limbal blood vessels. 
The PMN are activated to release more proangiogenic and angiogenic factors 
that expand the vascular bed. Once sufficient in extent, these leaky vessels act 
as conduits for T cells which now include the HSV specific T cells from 
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lymph nodes. Meanwhile, viral antigens are taken up and processed by DCs 
which present them to viral antigen specific CD4+ T cells. These respond by 
releasing more inflammatory mediators which serve to recruit and activate 
additional T cells, most of which are now not HSV specific and some of which 
may be autoreactive. These recruits release more inflammatory molecules 
(bystander activation) in a positive feedback loop that gradually ceases as 
levels of activators fall and terminators increase (Fig 4B, 5). The stroma is left 
with a damaged matrix and unwanted vascular bed that is slow to resolve. 
Current studies are ongoing to verify this pathogenesis scheme of events. 
CONCLUSION 
In conclusion, the pathogenesis of SK, as revealed by animal studies, is 
complex. Virus replication is necessary for the lesions but may not be directly 
involved in driving the chronic immunopathology. Many early events caused 
by virus have been identified and shown to form part of the process. The 
mystery remains as to mechanistic events which account for the chronic 
progressive lesion that impairs vision. One hopes that understanding this 
process could reveal clues that may help control this unfortunate disease. 
SPECIFIC AIMS AND RATIONALE 
Studies with the mouse model for HSK have revealed the involvement of 
complex cellular and molecular mechanisms in its pathogenesis. Several areas, 
both in the clinical and pre-clinical phase, require further elucidation. These 
include viral replication, the early proinflammatory events, innate and 
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adaptive immune cell influx and neovasculariztion of the avascular cornea. 
Understanding these early events is critical, since many of these early events 
are subject to modulation providing an approach to controlling this important 
cause of human blindness. Studies described here have been aimed at 
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Fig 1. Crucial events in HSK pathogenesis. 
Following Herpes simplex virus type 1 (HSV -1) infection replicating virus is 
detectable in the cornea till 5- 6 days p. i. Viral mRNA is detectable till 7- 8 
days p. i. However viral DNA persists in the cornea till day 20 p. i. 
Angiogenesis or new blood vessel development from existing limbal vessels 
starts at 24 hr pj. and gradually peaks around day 15 p. i. The early cell influx 
in the corneal stroma is dominated by polymorphonuclear leukocytes (PMN). 
PMN influx is characterized by a typical biphasic response. This response 
starts around 18 hr p. i., peaks at 48 hr p. i., declines around 5 days pj. and 
then comes back during the clinical phase. Whereas the T cells enter the 
cornea during the clinical phase around 8-9 days p. i. 
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Fig 2. Schematic representation ofsome early events in HSK pathogenesis. 
Herpes simplex virus type 1 (HSV -1) infection of the corneal epithelial cell 
layer resulted in the production of plethora of proinflammtory cytokines and 
chemokines early after infection. These cytokines and chemokines create an 
inflammatory milieu that makes the corneal environment favorable for a 
prompt inflammatory cell influx such as polymorphonuclear leukocyte 
(PMN), macrophages and natural killer cells (NK cells). The set is also set for 
subsequent events that continue into the clinical phase such as tissue 
destruction by PMN (mainly neutrophil) and corneal neovascularization which 
is mainly regulated by an interplay between angiogenic factors (VEGF, MMP­
9) and antiangiogenic factors (IP-I0). Newly developed blood vessels in 
corneal stroma in tum act as a conduit for inflammatory cell influx during the 
clinical phase. Question mark (?) indicates identity of factors responsible for 
paracrine IL-12 production is not known. 
Abbreviations: IL, Interleukin; IFN-y, Interferon gamma; VEGF, vascular 
endothelial growth factor; COX-2, Cycloxygenase 2; PGE2, Prostaglandin 
MIP-2, Macrophage Inflammatory protein 2; IP-I0, Interferon inducible 
protein 10; MiG, Monokine induced by IFN-y; PECAM 1, Platelet endothelial 
cell adhesion molecule 1; MHC II, Major Histocompatibility complex II; 
MMP-9, Matrix metallo proteinase 9; PMN, Ploymorphonuclear leukocyte, 
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Fig 3. The molecular mimicry model ofSK pathogenesis 
The figure summarizes the relative roles of molecular mimicry and 
nonspecific inflammation in SK pathogenesis. This concept explains that the 
virus replication and non specific immune responses some how unmasks 
autoantigens in the eye and additionally stimulates an antiviral T cell 
responses that is cross-reactive with the corneal autoantigens. 
46 
Fig 4A and B. The Bystander activation model ofSK pathogenesis. 
A summary of events initiated at the preclinical phase and ending in the 
clinical phase of herpetic stromal keratitis is shown in both immunocompetent 
and immunocompromised model. The inflammatory events set off by viral 
replication continue into the clinical phase. In immunocompetent animals 
these molecules play important role in ingress and subsequent activation of 
neutrophils and DCs in the stroma and angiogenic sprouting from the limbal 
blood vessels. These blood vessels act as conduits for T cells which now 
include the HSV specific T cells from lymph nodes. Meanwhile, viral antigens 
are taken up and processed by DCs which present them to viral antigen 
specific CD4+ T cells. These respond by releasing more inflammatory 
mediators which serve to recruit and activate additional T cells, most of which 
are now not HSV specific and some of which may be autoreactive. However, 
in immunocompromised animals inflammatory molecules produced as a 
consequence of ocular HSV infection activate the T cells in a non TCR 
mediated manner. In this instance, virus persisted and spread to the stromal 
tissue location in some way. This continually replicating virus in the corneal 
stroma acts, possibly by TLR ligand activity, as the chronic stimulus for 
cytokine Ichemokine production that in tum activates the incoming T cells. 
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Fig 5. The Hit and Run model ofSK pathogenesis. 
HSV-1 replication is required to marshal a complex of molecular events, 
which we term the "alarm complex". These molecules serves directly or 
indirectly to signal the ingress and subsequent activation of innate immune 
cells in the stroma and angiogenic sprouting from the limbal blood vessels. 
The innate immune cells are activated to release more proangiogenic and 
angiogenic factors that expand the vascular bed. Once sufficient in extent, 
these leaky vessels act as conduits for adaptive immune cells (T cells) which 
now include the HSV specific T cells from lymph node. These T cells in tum 
produce more inflammatory mediators which serve to recruit and activate 
additional T cells, most of which are now not HSV specific and some of which 
may be autoreactive. These recruits release more inflammatory molecules 
(bystander activation) in a positive feedback loop. The stroma is left with a 
damaged matrix and unwanted vascular bed that is slow to resolve. The dotted 
arrow and the question mark indicate that still no evidence is available about 




' ,...;,. ,)~--.:..... .. 
Malecul;n events 












An.l'a.eJt'nesl's :=======-: Cellular events 





MICE TRANSGENIC FOR IL-l RECEPTOR 

ANTAGONIST PROTEIN ARE RESISTANT 

TO HERPETIC STROMAL KERATITIS: 

POSSIBLE ROLE FOR IL-l IN HERPETIC 





Research described in this chapter is a slightly modified version of an article 
published in 2004 in The Journal of Immunology by Partha Sarathi Biswas, 
Kaustuv Banerjee, Bumseok Kim and Barry T. Rouse. 
Biswas, P. S., K. Banerjee, B. Kim, and B. T. Rouse. 2004. Mice transgenic 
for IL-l receptor antagonist protein are resistant to herpetic stromal keratitis: 
possible role for IL-l in herpetic stromal keratitis pathogenesis. J. Immunol. 
172: 3736. Copyright 2004. The American Association ofImmunologists, Inc. 
In this chapter "we" and "our" refers to co-authors and me. My contributions 
in the paper include (1) selection of the topic (2) data analysis and 
interpretation (3) planning experiments (4) compiling and interpretation of the 
literature (5) understanding how results fit with the literature (7) compilation 
of contributions into one paper (8) providing structure to the paper (9) making 
graphs, figures and tables (10) writing and editing. 
ABSTRACT 
Ocular infection with herpes simplex virus (HSV) may result in the blinding 
immunoinflammatory lesion Stromal Keratitis (SK). Early events in the 
pathogenesis that set the stage for SK are poorly understood. The present 
report evaluates the role of IL-l using a transgenic mouse that overexpresses 
the IL-l receptor antagonist protein. Such transgenic mice were markedly 
resistant to SK compared to IL-l Ra -/- and C57BU6 control animals. 
Targeting IL-l could prove to be a worthwhile therapeutic approach to control 




Herpes simplex virus (HSV) infection is a major cause of vision loss (1). This 
results mainly from a chronic inflammatory reaction in the normally 
transparent and avascular cornea. A complex of humoral and cellular events 
are involved in the pathogenesis of SK, but the critical event responsible for 
clinically evident lesions is CD4+ T cell mediated immunopathology (2, 3). 
Prior to the T cell mediated immunoinflammatory phase, multiple events 
occur after virus infection that set the stage for the subsequent pathology. 
These events include the production of proinflammatory cytokines and 
chemokines and a prominent invasion of the cornea by PMN (4, 5). The later 
response appears protective and helps clear virus (4, 5). However, PMN 
invasion also contributes to pathology since the cells are a major source of 
angiogenesis factors (6) and perhaps also damaging factors such as NO (7). 
N eovascularization, represents a maj or step in SK pathogenesis and mUltiple 
molecules are involved in this process (8). It is not clear how HSV infection, 
which in the mouse model is usually confined to the corneal epithelium, 
results in neovascularization into the underlying stroma. Thus once a cell is 
productively infected by HSV most cellular proteins cease production (9). 
Exceptions include IL-6 (10, 11) and probably IL-l (12) which are briefly 
induced by HSV infection by mechanisms that remain undefined. These 
cytokines could represent key molecules that set off a cascade of events that 
culminate in the clinically evident immunoinflammatory lesions. After HSV 





infection and reached peak levels at day 10, and then diminished over the next 
few days (13, 14). In consequence, counteracting IL-l and IL-6 could be a 
valuable control measure at least if performed early after infection. The aim of 
this study was to determine if inhibition of IL-l, as could be achieved by using 
a transgenic mouse that overexpressed the IL-l receptor antagonist, had an 
effect on SK pathogenesis. Such transgenic mice have been used in other 
inflammatory models and were shown to block IL-l and diminish disease 
expression (15-18). Our results with ocular infection with HSV demonstrate 
that IL-l Ra Tg mice developed significantly milder disease and reduced 
corneal angiogenesis compared to IL-l Ra -/- and C57BU6 mice. This 
difference in disease phenotype was an indirect event and was shown to be the 
consequence of changed expression of molecules such as IL-6, MIP-2 and the 
angiogenesis factor VEGF normally unregulated by IL-l during an 
inflammatory process (19-21). Our results demonstrate that IL-l production is 
a critical event in SK pathogenesis and that inhibiting this cytokine represents 
a valuable approach for disease control. 
MATERIALS AND METHODS 
Mice 
IL-l receptor antagonist transgenic (T14 hemizygous line) and knockout mice 
were kindly provided by Dr. David Hirsh (Department of Biochemistry and 
Molecular Biophysics, College of Physician and Surgeons, Columbia 
University). Wild type female 4 to 5 weeks old C57BU6 mice were purchased 
from Harlan Sprague-Dawley (Indianapolis, Indiana). Animals were sex and 
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age matched for all experiments. All manipulations involving the 
immunocompromized mice were performed in a laminar flow hood. To 
prevent bacterial superinfections, all mice received prophylactic treatment 
with Sulphatrim pediatric suspension (Barre-National Baltimore, MD). All 
experimental procedures were in complete agreement with the Association for 
Research in Vision and Ophthalmology (ARVO) resolution on th,e use of 
animals in research. 
Virus 
HSV-l RE (obtained from Dr. Robert Hendricks Laboratory, University of 
Pittsburgh School of Medicine) was used in the present study. The virus was 
propagated and titrated on monolayers of Vero cells (A TCC, Cat No. CCL81) 
using standard protocols (22). Infected Vero cells were harvested, titrated and 
stored in aliquots at _80 
0 
C until used. 
Corneal HSV -1 infection 
Corneal infections of all mice groups were conducted under deep anesthesia 
induced by intraperitoneal injection of A vertin (Sigma). Mice were scarified 
on their corneas with a 27-gauge needle and a 4J..lI drop containing the required 





Clinical observations and Angiogenesis Scoring 
The eyes were examined on different days post infection by a slit-lamp 
biomicroscope (Kowa Co. Nagoya, Japan), and the clinical severity of keratitis 
of individually scored mice was recorded as described before (8). 
Angiogenesis severity was measured as described previously (23). Briefly, a 
grade of 4 for a given quadrant of the circle represents a centripetal growth of 
1.5mm toward the corneal center. The score of the 4 quadrants of the eye were 
then summed to derive the NV index (range 0-16) for each eye at a given 
point. 
In vitro stimulation of corneal epithelial cell culture 
Isolation of corneal epithelium cells were performed as described before (24). 
Briefly corneal buttons were incubated at 3i C in phosphate buffered saline 
containing 10mM tetra sodium diaminetetracetate dehydrate (Sigma) for 45 
minutes. After incubation, the epithelial cell layer. was separated from the 
adjacent corneal tissue by gentle teasing with a fine forceps. The intact 
epithelial layer was washed several times in PBS followed by treatment with 
collagenase D (Roche) at 37° C for 30 minutes. The disrupted epithelial cells 
were then passed through a 40Jlm filter to make a single cell suspension. Cells 
were counted and suspended in F-12K medium (A TCC) with 10% FCS and 
plated in 48 well tissue culture plates at 3i C in 5% C02. Purity of cultured 
corneal epithelial cells was determined by flow cytometry using anti K12 
antibody (kindly provided by Dr. Winston Kao, University of Cincinnati). The 
corneal epithelial cell culture yielded 75-80% purity. 
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Adherent monolayer of epithelial cells was stimulated with different 
doses of recombinant murine IL-l a and IL-l ~ (R & D systems) in serum free 
F-12 K medium for 24hr and 48hr. After incubation, the supernatant was 
collected and stored at _80
0 
C till further use. For blocking studies, different 
doses of anti-murine IL-1a antibody (Pharmingen) was mixed with 800pg 
(dose selected on the basis of dose response curve) of IL-1a. Rat IgG was 
used as isotype control. 
Corneal intrastromal injection assay 
Corneal intrastromal injection was performed as described before ct).Under 
direct stereomicroscopic .observation, a nick in the epithelium and anterior 
stroma of mouse cornea was made with a Yl- inch 30-gauge needle with a 30 
0 
bevel in the mid periphery. Eight eyes were injected per group. The needle 
was introduced into the corneal stroma and advanced 1.5 mm to the corneal 
center. Two microlitres of solution containing the required concentration of 
recombinant murine IL-1a (lOOng, 200ng and 400ng) (Pharmingen) and anti 
murine VEGF antibody [5J.!g (25)](R & D system) was forcibly injected into 
the stroma to separate the corneal lamellae and disperse the solution. PBS was 
used as control. 
Subconjunctival inoculations 
Subconjunctival inoculation of recombinant murine IL-6 [50ng (26)] 
(Pharmingen) and anti murine 1L-6 antibody [5J.!g/JlI (26)] was performed as 
described previously (26). Briefly, subconjunctival inoculations were done 
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using a 2 cm 32 gauge needle and syringe (Hamilton) to penetrate the 
perivascular region of conjunctiva and deliver 4JlI into the subconjunctival 
space. Control mice received PBS. Mice received recombinant murine IL-6 a 
day before corneal infection with HSV -1 RE. 
Viral titration 
Eye swabs were taken from the infected corneas (3 mice/group) using sterile 
cotton swabs soaked in DMEM containing 10 IU/ml penicillin and 100Jlg /ml 
streptomycin. All manipulations are done under sterile conditions. Swabs were 
stored in tubes containing serum free DMEM at _80 
0 
C. For detection of virus, 
samples were thawed and vortexed. Duplicate samples (200JlI) were plated on 
Vero cells grown to confluence in 24 well plates at 37°C in 5% C02 for 90 
minutes. Medium was aspirated and 500JlI of DMEM containing 1 % LMP 
agarose was added to each well. Titers were calculated as 10glO pfu/ml as per 
standard protocol (22). 
Histopatbolgy 
For histopathological analysis, eyes were extirpated and fixed in 10% buffered 
neutral formalin. Staining was performed with Hematoxylin and Eosin 
(Richard Allen Scientific, MI). 
RT-PCR 
Total RNA from 4 corneas per time point was extracted by using Tri-reagent 
(Molecular Biology Inc., Cincinnati, Ohio). Total RNA (1 Jlg) was reverse 
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transcribed using murine leukemia virus reverse transcriptase (Gibco BRL 
Life Technologies, Bethesda MD) with oligodT as primer (Invitrogen, CA). 
All cDNA samples were aliquoted and stored at -20°C until further use. 
Polymerase chain reaction was performed in PTC-1oo Programmable Thermal 
Controller (MJ Research Inc.) using Hot Start PCR Master Mix (Promega, 
WI). The primers used were murine GAPDH Forward 
CATCCTGCACCACCAACTGCTTAG Reverse 
GCCTGCTTCACCACCTTCTTGATG and murine IL-1 Ra Tg Forward 
TAGACATGGTGCCTATTGAC Reverse GAGGCTCACAGGACGGTCAG. 
Flow Cytometry 
Single-cell suspensions -were prepared from 4 corneas at 24 and 48 hr post 
infection as described elsewhere (27), with some modifications. Briefly, 
corneal buttons were incubated with collagenase D (Roche) for 60 min at 37°C 
in a humidified atmosphere at 5% CO2. After incubation, eyes were disrupted 
by grinding with a syringe plunger and passing through a cell strainer. Cells 
were washed and suspended in RPMI 1640 with 10% FBS. The Fc receptors on 
the cells were blocked with unconjugated anti-CD16/32 (Pharmingen) for 30 
min. Samples were incubated with FITC labeled anti Gr-1 antibody (Clone 
RB6-8C5, Pharmingen) and isotype controls for 30 minutes. All samples were 
collected on a FACScan (BD Biosciences), and data were analyzed using 
CellQuest 3.1 software (BD Biosciences). 
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Cytokine ELISA of corneal lysate 
For preparation of corneal lysates, 6 corneas per time point were pooled and 
minced. All procedures were done on an ice bath. Minced pieces were 
collected in 1ml DMEM without FCS and homogenized using a tissue 
homogenizer (PRO Scientific Inc., Mourse) four times, 15 seconds each, 
with a gap of 1 minute between homogenization to allow the sample to cool. 
The lysate was then clarified by centrifugation at 14,000 rpm for 5 minute at 
4°C. The supernatant was collected and used immediately or stored at _80°C 
until further use. Lysates were analyzed using a standard sandwich ELISA 
protocol. Anti IL-6 capture and biotinylated detection antibodies were from 
Pharmingen (Clone MP5-20F3) and standard recombinant murine IL-6 was 
from R&D Systems Inc, Minneapolis. Anti MIP-2 and anti VEGF164 capture 
and biotinylated detection antibodies and recombinant standards for murine 
MIP-2 and murine VEGF164 were from R&D Systems. The color reaction 
was developed using ABTS (Sigma) and measured with an ELISA reader 
(Spectramax 340, Molecular Devices) at 405nm. The detection limit was 
2pg/ml. Quantification was performed with Spectramax ELISA reader 
software version 1.2. 
Quantitative real time PCR 
Total RNA from 4 corneas per time point was extracted by using RNeasy 
RNA extraction Kit (Qiagen, CA). Briefly, tissues were lysed in RLT buffer 
and RNA was purified following manufacturer's instructions (Qiagen, CA). 
DNAse treatment (Qiagen, CA) was done to remove any contaminating 
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genomic DNA. To generate cDNA, 1Jlg total RNA was reverse transcribed 
using murine leukemia virus reverse transcriptase (Gibco BRL Life 
Technologies, Bethesda MD) with oligodT as primer (Invitrogen, CA), 
according to manufacturer's instructions. All cDNA samples were aliquoted 
and stored at -20°C until further use. 
Real time PCR was performed using a DNA Engine Opticon (MJ 
Research Inc.). PCR was performed using SYBR Green I reagent (Qiagen, 
CA) according to manufacturer's protocol. PCR amplification of house 
keeping gene, murine glyceraldehyde 3-phosphate dehydrogenase was done 
for each sample as a control for sample loading and to allow normalization 
between samples. A standard curve was constructed with PCR-II topo cloning 
vector (Invitrogen, CA) containing the inserted same fragment amplified by 
the SYBR I system. PCR reactions for each sample was analyzed in three 
dilutions in duplicate for both GAPDH and target gene. The target gene was 
then normalized to 106 copies of GAPDH control and data represented as copy 
numbersll 06GAPDH. The primers used were murine GAPDH Forward 
CATCCTGCACCACCAACTGCTTAG Reverse 
GCCTGCTTCACCACCTTCTTGATG and murine VEGFR-2 Forward 









IL-l Ra Tg mice show reduced Stromal Keratitis and corneal 
angiogenesis 
Three groups of genetically different mice, IL-l Ra Tg, IL-l Ra -/- and wild 
type C57BU6, were evaluated clinically for the development of SK following 
HSV-l (5xl06 pfu) corneal infection over a 20 day test period. NaIve and 
infected corneas of IL-l Ra Tg mice demonstrated higher level of IL-l Ra 
mRNA in comparison to wild type control (Fig. 1). As shown in Fig. 2A, 
whereas the pattern and severity of SK in both IL-l Ra -/- and wild type 
C57BU6 mice was similar (mean scores 3.5 and 2.7 respectively), SK in IL-l 
Ra Tg mice was strikingly reduced (mean score of 1.4) (Fig. 2A). In addition 
whilst 75% of eyes of IL-l Ra -/- mice developed clinically evident lesions 
(score 3 or greater), only 25% of IL-l Ra Tg mice developed such lesions 
(data not shown). Attempts to infect IL-l Ra Tg mice with a higher virus dose 
(107 pfu) resulted in lethality, but still few developed SK of ~ 3 (data not 
shown). Histopathological analysis of representative eyes of IL-l Ra Tg mice 
revealed mild inflammatory changes and cellular infiltrations in the corneal 
stroma and epithelium at day 20 p. i. (Fig. 2B). However both IL-l Ra -/- and 
C57BU6 mice developed more severe inflammatory changes (Fig. 2B). 
One characteristic of corneal HSV -1 infection is neovascularization 
into the normally avascular corneal stroma, an event deemed necessary for the 
full expression of SK (28). In comparison to the extent of angiogenesis 
following HSV infection in IL-l Ra -/- and C57BU6, the eyes of IL-l Ra Tg 
mice revealed marked reduction of this process (Fig 3A, 3C). By day 20 p. i, 
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the angiogenesis score was greater than lOin 13 of 16 IL-1 Ra -/- eyes and 8 
of 16 C57Bl16 mice (Fig 3B) but only 4 out of 16 eyes of IL-1 Ra Tg mice 
had such a score (Fig 3B). Taken together these results indicate that 
overexpression of IL-1 Ra protein led to diminished angiogenesis as well as 
stromal keratitis. 
PMN inflammatory response in IL-l Ra Tg mice: 
A major event following ocular infection with HSV is a prompt PMN influx 
into the corneal stroma (4, 5). This reaction at 24 and 48 hr p. i. was 
significantly less in IL-1 Ra Tg mice compared to either IL-1 Ra -/- and wild 
type mice (Fig. 4, Table 1). PMN are considered as involved in antiviral 
defense (4, 5). In line with this notion viral clearance was impaired in IL-1 Ra 
Tg mice compared to IL-l Ra -/- and wild type mice (Table 2). Accordingly 
virus was present in ocular swabs for around 2 extra days in IL-1 Ra Tg mice 
(Table 2). 
One reason considered for the scant PMN response in IL-l Ra Tg mice 
was that IL-1, must, in nonnal situations serves to induce molecules that are 
directly or indirectly chemotactic for PMN. Based on the results of others (26, 
29) prime candidates considered were IL-6 and MIP-2. Levels of these 
proteins were compared in the 3 mouse strains at various time points after 
HSV infection. Both IL-6 and MIP-2 protein levels in corneal extracts were 
significantly less in IL-l Ra Tg mice compared to IL-1 Ra -/- and wild type 
animals at all time points analyzed (Fig. 5A & 5B). In addition, if recombinant 






day prior to corneal infection, there was an approximately 4 fold increase in 
PMN influx in HSV infected IL-I Ra Tg mice compared to controls given 
PBS (Fig. 6A, Table 3). Such eyes demonstrated a higher IL-6 level in 
comparison to PBS control at day 2 post injection (data not shown). 
Furthermore, IL-6 reconstitution also resulted in significantly higher levels 
(p<O.05) of the chemokine MIP-2 in corneal extracts (Fig. 6B). 
To evaluate which corneal cells might act as a source of IL-6 upon IL­
stimulation, corneal epithelial cell cultures were stimulated in vitro with 
different doses of recornbinant IL-Ia and IL-I~. Interleukin-Ia, but not IL­
l~, could induce IL-6 production from corneal epithelial cells in a dose 
dependent 111allner at 24 hr and 48 hr (Fig. 7 A). The presence of neutralizing 
antibody against murine IL-Ia, but not control IgG, blocked the IL-6 
production from these cells in a dose dependent manner (Fig. 7B). 
Environment favorable for corneal angiogenesis is severely compromised 
in IL-l Ra Tg mice 
As noted above, IL-I Ra Tg mice developed markedly diminished angiogenic 
responses compared to either IL-I Ra -/- and wild type controls. Protein levels 
of VEGF was significantly lower (p<O.05) in IL-I Ra Tg mice compared to 
IL-I Ra -/- and C57BL/6 animals at all time points analyzed (Fig. 8A). In 
addition, real time PCR demonstrated a significantly higher level of VEGFR-2 
mRNA transcript in IL-I Ra -/- and C57BU6 mice than in IL-I Ra Tg animals 
(Fig.8B). 
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Previous studies demonstrated that IL-I a could upregulate the 
angiogenesis factor VEGF in human PBMC in vitro (20). To demonstrate the 
angiogenic activity of IL-Ia in murine cornea, different doses of recombinant 
murine IL-I a was injected intrastromally and the extent of angiogenesis was 
measured at day 2 and 4 days postinjection. Corneal ELISA revealed a 
significant increase in IL-I a level at day 2 post injection in comparison to 
PBS control (data not shown). Interestingly, IL-Ia induced a dose dependent 
angiogenic response (Fig. 9A, 9B). In such eyes, both IL-6 and VEGF protein 
levels were elevated (Fig. lOA, lOB). Administration of neutralizing antibody 
against murine VEGF could abrogate IL-I a induced angiogenesis 
demonstrating the key involvement of VEGF in this process (Fig. IIA). Such 
eyes demonstrated diminished VEGF level in comparison to IgG control (data 
not shown). In order to rule out the possible involvement of IL-6 in the IL-I a 
mediated corneal angiogenesis, anti IL-6 antibody was administered with IL­
Ia protein. Interestingly the presence of neutralizing antibody against IL-6 
reduced, but did not abrogate IL-Ia induced corneal angiogenesis (Fig. lIB). 
DISCUSSION 
This report deals with early events in the pathogenesis of the blinding 
immunoinflammatory lesion Stromal Keratitis caused by ocular infection with 
HSV. Our results demonstrate that transgenic mice that overexpress the IL-I 
receptor antagonist protein are markedly resistant to SK compared to control 




expression of molecules usually induced by IL-l, which in tum participate in 
inflammatory cell recruitment and angiogenesis. In the present report, we 
evaluate the critical role of IL-l using a transgenic mouse that overexpress IL­
l receptor antagonist protein. Thus IL-l Ra Tg mice had reduced levels IL-6, 
the chemokine MIP-2; as well the angiogenesis factor VEGF and its receptor 
VEGFR-2. In consequence, the IL-l Ra Tg mice showed less PMN influx and 
neovascularization than did control C57BU6 animals. Our results imply that 
blocking IL-l activity could represent a valuable therapeutic approach to 
control SK. 
One striking difference noted between C57BU6 control and IL-l Ra Tg 
mice was a marked difference in PMN invasion 2 days post HSV infection. 
This early PMN response was shown previously to be in part responsible for 
viral clearance (4, 5). This viewpoint was also supported by the present 
studies. Thus, IL-l Ra Tg mice, which expressed a diminished PMN response, 
also showed a delay in viral clearance. How IL-l in normal infected mice 
causes PMN influx remains unclear. However, since IL-l itself is not 
chemotactic for PMN (30), the effect must be indirect, with IL-l inducing one 
or more chemokines. A likely candidate is MIP-2, since MIP-2 neutralized 
mice develop minimal PMN responses to ocular HSV infection (29). The 
results of the present study indicate that IL-l did induce MIP-2 but this was an 
indirect consequence of IL-6 induction. In support, IL-l a was shown to 
induce IL-6 in vitro in corneal epithelial cells. In addition, MIP-2, as well as 
other chemokines, such as MIP-l a and MCP-l, were shown by others to be 
induced by IL-6 (26, 31). Our studies also demonstrated that IL-l was 
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upregulated in virus infected corneal epithelial cells (data not shown). This 
observation as well as others (10-12) indicates that HSV infection results in 
the autocrine production of IL-l as well as IL-6. This process may be brief 
since as HSV infection proceeds, host mRNA synthesis and protein translation 
is inhibited in productively infected cells (9). However, IL-l also drives IL-6 
production by uninfected cells, which together with that produced by infected 
cells themselves, sets off a cascade of events that result in PMN influx. 
Supporting the scheme we could show that the provision of exogenous IL-6 
intrastromally to the transgenic mice, reconstituted the PMN invasion. 
Although PMN playa protective function in HSV ocular infection, they 
also participate in lesion expression and act as a source of angiogenesis factors 
(6) as well as molecules such as nitric oxide (7) that damage corneal tissues. 
Thus, in line with the minimal early PMN response noted in IL-l Ra Tg mice, 
such animals showed a marked reduction in angiogenesis compared to 
controls. One factor derived from PMN, as well as from other cell types 
involved in neovascularization, is VEGF (32, 33). We demonstrated that 
VEGF was significantly downregulated in IL-1 Ra Tg mice in comparison to 
control animals. Similar observations were reported previously in a 
nonspecific model of ocular inflammation (34). The diminished VEGF 
response of transgenic mice may be explained by the fact that the presence of 
the IL-l receptor antagonist suppressed IL-l induced VEGF production from 
uninfected corneal cells such as PMN. Previously, HSV infection was shown 
to cause VEGF production but not from the cells actually infected with virus 








the paracrine induction of VEGF. Supporting this scheme, the presence of IL­
Ra suppressed the VEGF response. In addition, the angiogenic response 
induced in mice by intrastromal injection of IL-l could be largely inhibited by 
anti VEGF antibody. Furthermore, intrastromal injection of IL-la was shown 
to induce VEGF in the cornea. These observations as well as others in tumor 
systems (20, 35) indicate that IL-l can cause cells to produce VEGF. 
Even though IL-l produced from HSV infected cells may act as an inducer 
for VEGF production, an additional VEGF stimulant appeared to be mediated 
by the cytokine IL-6. Thus we demonstrated that corneal cells exposed to IL-l 
in vitro produce IL-6, and IL-6 was shown previously to be a strong agonist 
for VEGF production «36, 37). Further support that IL-l induced 
angiogenesis depended in part on IL-6 production was the observation that it 
was partially blocked by anti IL-6 antibody. The relative importance of the 
direct and indirect effect of IL-l on VEGF production and angiogenesis 
remains to be evaluated. 
Finally, our results demonstrated that corneal RNA samples from 
transgenic mice showed diminished VEGFR-2 levels measured by Real Time 
peR. In tumor systems, IL-l was shown to upregulate VEGFR-2 expression 
on endothelial cells (38), the latter known to be critical for pathological 
angiogenesis (39). Evidently, the absence of IL-l activity, as occurred in IL-l 
Ra Tg mice, results in reduced expression of VEGFR-2. The consequence is 
lack of stimulation for the endothelial cells to proliferate, resulting in reduced 
angiogenesis. However it is not clear why transgenic mice demonstrated 
reduced VEGFR-2 expression. We believe there may be two possibilities. 
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Firstly, IL-l may directly upregulate VEGFR-2 expression on corneal 
endothelial cells and blocking its activity by specific antagonist protein results 
reduced receptor expression. Secondly, reduced proliferation of endothelial 
cells as a consequence of diminished VEGF and inflammatory response in 
these mice. Weare currently attempting to ascertain which of these two 
mechanisms accounts for the major effect of IL-l on angiogenesis. 
Taken together, our results support the hypothesis that the inflammatory 
milieu and angiogenic stimuli created early after infection play an important 
role in HSV induced ocular lesions. An important participant of this 
environment is IL-l. Antagonizing the effect of IL-l by a specific receptor 
antagonist protein abrog3:tes the cascade of events that culminate in HSK. This 
regulation is indirectly mediated by downregulating various signaling 
molecules previously known to be hnportant in HSK pathogenesis and corneal 
angiogenesis. It would seem that targeting IL-l could prove to be a 
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Fig 1. Expression of corneal IL-l Ra mRNA at various time points after 
HSV infection 
At different time points p. i., corneas (n = 4) were isolated and total RNA was 
extracted using Tri-Reagent. Total RNA (lJlg) was converted into cDNA as 
described in the materials and methods. Polymerase chain reaction was 
performed in PTC-100 Programmable Thermal Controller, M J Research 
Incorporation. Murine GAPDH served as internal control. Lane M- Molecular 
weight marker; Lane 1- C57BU6 naIve; Lane 2- C57BU6 day 2 p. i.; Lane 3­
C57BU6 day 5 p. i.; Lane 4- IL-1 Ra Tg naIve; Lane 5- IL-1 Ra Tg day 2 p. i.; 
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Fig 2. Reduced HSK severity in IL-J Ra Tg mice 
A. Mean lesion HSK score at day 20 p. i. of mice infected with 5x106 pfu 
HSV-1 RE. Each dot represents the HSK score from one eye. Horizontal bars 
and figures in the parenthesis indicate the mean for each group. Data is 
compiled from two separate experiments consisting of 8 eyes in each group. 
B. Mice were infected with 5x106 pfu HSV-1 RE. Mice were terminated at day 
20 p. i. and eyes were processed for paraffin embedding. Hematoxylin and 
Eosin staining was carried out on 6Jl sections. Magnification x 200. 
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Fig 3. IL-l Ra Tg mice show reduced angiogenic response following HSV-l 
infection at day 20 p. i. 
A. Kinetics of corneal neovascularization process in mice infected with 5xI06 
pfu HSV -1 RE. Angiogenesis scores were recorded as mentioned in the 
Materials and Methods at indicated time points. Data is compiled from two 
separate experiments involving 8 eyes per group and is expressed as Mean ± 
SD. *Statistically significant differences in angiogenesis score (p< 0.05) were 
observed between IL-I Ra Tg mice to either IL-I Ra KlO and C57BU6 mice. 
B. Angiogenesis scores for individual eyes of IL-I Ra Tg, IL-iRa -1- and 
C57BU6 mice infected with 5xI06 pfu HSV-I RE at day 20 p. i. Horizontal 
bars and figures show the mean for each group. Data are compiled from two 
separate experiments consisting of 8 eyes per group. *Statistically significant 
differences in angiogenesis score (p< 0.05) were observed between IL-I Ra Tg 
mice to either IL-I Ra KlO and C57BU6 mice. 
C. At day 20 p. i. extensive growth of blood vessels can be seen in IL-I Ra -l­
and C57BU6 mice infected with 5xI06 pfu HSV-I RE. IL-I Ra Tg mice show 
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Fig 4. Presence of abundant Gr-I +ve cells in the cornea of [L-I Ra -/- and 
C57BU6 mice but not in [L-I Ra Tg mice at 48 hr p. i. 
Single cell suspensions of corneal cells were prepared from 4 eyes at 24 and 
48 hr p. i. The cells were counted and stained with FITC labeled anti Gr-l 
antibody and numbers of Gr-l positive cells were enumerated by FACS. 
Histogram is representative of one of three separate experiments. Shaded and 
open histogram represents Gr-l +ve cells at day 2 p. i. from uninfected and 
infected corneas respectively. 
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Fig 5. Reduced IL-6 and MIP-2 protein levels in HSV-l infected corneas of 
IL-l Ra Tg mice. 
A & B. At indicated time points, 6 corneas / group were processed for 
measuring the IL-6 and MIP-2 protein levels. Levels of IL-6 and MIP-2 was 
estimated from supernatants of corneallysates of mice infected with 5x106 pfu 
HSV-1 RE by an antibody capture ELISA as outlined in materials and 
methods. Results are expressed as Mean ± SD of three separate experiments (6 
corneas/time point). *Statistically significant differences in IL-6 and MIP-2 
level (p< 0.05) were observed between IL-1 ra Tg mice to either IL-I Ra KlO 
and C57BU6 mice at all time points analyzed. 
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Fig 6. Increased Gr-l+ve cells and MIP-2 levels in recombinant murine IL­
6 reconstituted I L-l Ra Tg corneas at 48 hr p. i. 
A. Mice transgenic for IL-I Ra protein received recombinant murine IL-6 
(50ng) subconjunctivally 24 hr before corneal HSV -1 infection. PBS was used 
as negative control. Single cell suspensions of corneal cells were prepared 
from 4 eyes at 24 and 48 hr p. i. The cells were counted and stained with FITC 
labeled anti Gr-I antibody and numbers of Gr-I positive cells were 
enumerated by FACS. Histogram is representative of one of three separate 
experiments. Shaded and open histogram represents Gr-I +ve cells at day 2 p. 
i. from PBS and IL-6 reconstituted corneas of IL-I Ra Tg mice respectively. 
B. At 48 hr p. i., 6 corneas each from IL-6 reconstituted and PBS control 
group were processed to measure the MIP-2 protein levels. Levels of MIP-2 
was estimated from supernatants of corneal lysates of mice infected with 
5xI06 pfu HSV-1 RE by an antibody capture ELISA as outlined in materials 
and methods. Results are expressed as Mean ± SD of three separate 
experiments (6 corneas/time point). *Significant difference (p<O.05) compared 
to PBS treatment. 
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Fig 7. fL-I «induced fL-6 production/rom corneal epithelial cells. 
A. Corneal epithelial cells were stimulated with different doses of recombinant 
murine IL-l a for 24 and 48 hr. Supernatants were collected and levels of IL-6 
production was measured by an antibody capture ELISA as outlined in 
materials and methods. Results are expressed as mean ± SD of three separate 
experiments. *Significant difference (p< 0.05) compared to media control. 
B. Corneal epithelial cells were stimulated with 800pg of recombinant murine 
IL-l a along with different doses of anti IL-l a antibody for 24 hr. 
Supernatants were collected and levels of IL-6 production was estimated by an 
antibody capture ELISA as outlined in materials and methods. Results are 
expressed as mean ± SD of three separate experiments (6 corneas/time point). 
*Significant difference (p< 0.05) compared to rat IgG control. 



















Fig 8. Reduced VEGF protein levels and diminished expression of VEGFR.. 
2 mRNA expression in HSV..I RE infected corneas ofIL- IRa Tg mice 
A. At indicated time points 6 corneas /group were processed to measure the 
VEGF protein levels. Levels of VEGF was estimated from supernatants of 
corneal lysates of mice infected with 5xI06 pfu HSV -1 RE by an antibody 
capture ELISA as outlined in materials and methods. Results are expressed as 
mean ± SD of three separate experiments (6 corneas/time point). *Statistically 
significant differences in VEGF level (p< 0.05) were observed between IL-l 
Ra Tg mice to either IL-I Ra KlO and C57BU6 mice. 
B. At 2, 5and 7 day postinfection 4 corneas/group were processed for the 
extraction of cellular mRNA. Real time PCR analysis was conducted to detect 
the VEGFR-2 mRNA expression in corneas of mice infected with 5xl06 pfu of 
HSV-1 as described in materials and methods. Results are shown as mean ± 
SD of three separate experiments. *Statistically significant differences 
(p<0.05) were noted in the expression of VEGFR-2 between IL-iRa Tg to IL­
1 Ra KlO and C57BU6 mice at 5 and 7 day p. i. aCopy number of the target 
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Fig 9. IL-l a induces angiogenesis in a corneal intrastromal injection assay 
A. Different concentrations of recombinant IL-l a (100ng, 200ng and 40Ong) 
was injected intrastromally into C57BU6 corneas (n=8) and angiogenesis 
scoring was carried out on days 2 and 4 post injection. VEGF (200ng) was 
used as a positive control and PBS as negative control. Results expressed as 
mean ± SD. *Significant difference (p<0.05) compared to PBS treatment. 
B. Representative photographs of eyes at day 2 post injection with 200ng IL­
l a showing finer blood vessel development than that seen with the same dose 
of VEGF (white arrows). The PBS control showing no blood vessel 
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Fig 10. IL-l ainduces IL-6 and VEGF production in the cornea 
A&B. Corneas of C57BL/6 mice were injected intrastromally with 200ng of 
recombinant murine IL-I a. Corneas were excised from mice after 48hr and 
processed for detection of IL-6 and VEGF from corneal lysates as described in 
materials and methods. Results are expressed as mean ± SD for three separate 
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Figl1. Neutralizing antibody against VEGF but not IL-6 can abrogate IL­
l ainduced angiogenesis in the cornea. 
A. Corneas (n=8) of C57BU6 mice were injected intrastromally with 200ng of 
recombinant murine IL-I a alone, 200ng of recombinant murine IL-I a and 
anti murine VEGF (5J.!g) antibody, anti murine VEGF (5J.!g) antibody only and 
PBS. Angiogenesis scoring was carried out on days 2 and 4 post injection. 
Results expressed as mean ± SD for three separate experiments. *Significant 
difference (p<O.05) compared to mice treated with IL-I a alone (200ng). 
**Significant difference (p<O.05) compared to mice treated with PBS. 
B. Corneas (n=8) of C57BU6 mice were injected intrastromally with 200ng of 
recombinant murine IL-I a alone, 200ng of recombinant murine IL-I a and 
anti murine IL-6 (5J.!g) antibody, anti murine IL-6 (5J.!g) antibody only and 
PBS. Angiogenesis scoring was carried out on days 2 and 4 post injection. 
Results expressed as mean ± SD for three separate experiments. *Significant 
difference (p<O.05) compared to mice treated with anti IL-6 antibody with IL­
Ia. ··Significant difference (p<O.05) compared to mice treated with only anti 
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Research described in this chapter is a slightly modified version of an article 
submitted for publication in the Experimental Eye Research published by 
Partha Sarathi Biswas, Kaustuv Banerjee, Paul R. Kinchington and Barry T. 
Rouse. 
In this chapter "we" and "our" refers to co-authors and me. My contributions 
in the paper include (1) selection of the topic (2) data analysis and 
interpretation (3) planning experiments (4) compiling and interpretation of the 
literature (5) understanding how results fit with the literature (7) compilation 
of contributions into one paper (8) providing structure to the paper (9) making 
graphs, figures and tables (10) writing and editing. 
ABSTRACT 
Following ocular HSV -1 infection neovascularization of the avascular cornea 
is a critical event in the pathogenesis of herpetic stromal keratitis. Previous 
reports indicate an essential role for proinflammatory cytokines in HSV 
induced angiogenesis. This present study evaluates the role of 
proinflammatory cytokines such as IL-6 in corneal angiogenesis following 
virus infection. Our in vivo and in vitro data indicate that IL-6 produced from 
virus infected cells can stimulate noninfected resident corneal cells and other 
inflammatory cells in a paracrine manner to secrete VEGF, a potent 
angiogenic factor. Antibody neutralization of IL-6 results in a significant 
decrease in the number of VEGF producing cells in the cornea. Thus our result 
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serve to further demonstrate the close relationship between proinflammatory 
cytokines and VEGF induced corneal neovascularization. 
INTRODUCTION 
Ocular Herpes simplex virus 1 (HSV -1) infection may result in a chronic 
iInmunoinflammatory lesion in the corneal stroma termed herpetic stromal 
keratitis (HSK). In the murine model of HSV-locular infection, the 
pathogenesis of stromal keratitis involves a CD4+ T cell mediated destruction 
of the cornea (1). However, prior to the immunoinflammatory phase, multiple 
events occur after virus infection that set the stage for the subsequent corneal 
pathology. These events .include the production of proinflammatory cytokines, 
chemokines and neovascularization of the normally avascular cornea (2, 3). 
Angiogenesis occurs and new blood vessels sprout from limbal vessels within 
24 h of HSV infection that eventually extend to the central cornea within 10­
15 days (3). Such angiogenesis impairs vision and appears necessary for the 
ingress of T cells responsible for orchestrating HSK and impairs vision (1). 
Thus, neovascularization represents a major step in HSK pathogenesis, and 
multiple molecules are involved in this process. One of these is vascular 
endothelial growth factor (VEGF) (4). However, it is not known how HSV 
infections, which in the mouse model are usually confined to the corneal 
epithelium, results in VEGF production and initiate the angiogenesis process 
in the underlying corneal stroma. Previous studies from our group 
demonstrated that, 24 hr p. i. uninfected corneal resident cells are the principal 
source of VEGF, indicating a possible paracrine effect. One hypothesis is that 
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molecules released from infected cells could stimulate other cell types to 
produce VEGF. After HSV infection, both IL-1 and IL-6 are abundant by day 
1 post infection (5, 6). These reach peak levels at day 10, and then diminish 
over the next few days (5, 6). Interleukin-1 produced from HSV -infected cells 
has been shown to be a potent VEGF inducer from uninfected resident corneal 
cells (7). 
In addition to IL-1 produced from HSV -infected cells which acts to 
induce VEGF production, the aim of this study was to determine whether 
cytokine IL-6 could act as an additional VEGF stimulant. Both in vitro and in 
vivo observations demonstrate that IL-6 can stimulate uninfected corneal 
epithelial cells and stromal fibroblast cell line to produce VEGF. In addition, 
inflammatory cells, a critical component of murine HSK, can also be 
stimulated to produce VEGF by IL-6. Taken together these results indicate 
that production of VEGF following HSV infection is a paracrine event with 
IL-6 produced from virus infected cells acting as one of the factors. Thus IL-6 
cause uninfected resident cells and inflammatory cells to produce VEGF 
which in tum led to corneal angiogenesis. 
MATERIALS AND METHODS 
Mice 
Wild-type female 6-8 weeks old Balb/c mice were purchased from Harlan 
Sprague Dawley (Indianapolis, IN). Animals were sex and age matched for all 
experiments. All experimental procedures were in complete agreement with 
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the Association for Research in Vision and Ophthalmology resolution on the 
use of animals in research. 
Virus 
The virus HSV -1 RE-gC-EGFP is a gC-null derivative of the virus strain 
HSV-1 RE (8) that expresses the EGFP gene under the control of the gC 
promoter at the gC locus. To construct this virus, a plasmid was 
derived in which the EGFP gene (obtained as an NheI-XbaI DNA fragment by 
restriction enzyme digestion of the commercial plasmid pEGFP-N1: 
Clontech Corp, Palo Alto, CA) was cloned directly into a unique NheI 
site in the plasmid pUC8-gC. The latter plasmid is a cloned 949 base 
pair PstI-EcoRI fragment (co-ordinated 95,811 to 96,789, given with 
respect to the HSV -1 genome sequence) containing the promoter of gC and 
the first part of the gC open reading frame, all in the vector pUC8. 
The final resulting construct contains EGFP flanked by gC sequences, 
with the EGFP gene under control of the gC promoter and fused in the 
correct reading frame with the first 6 amino acids of gC. In this 
plasmid, the EGFP gene is followed by part of the gC open reading frame. 
The flanking gC sequences thus enable genetic recombination of the EGFP 
into the gC locus of the HSV-1 genome. To derive recombinant virus, 
the plasmid was linearized and cotransfected with purified HSV-1 RE DNA 
into vero cells using the calcium phosphate precipitation method. 
Following four days of incubation at 37°C, progeny virus in which 




fluorescence under UV illumination. Fluorescent virus was then plaque 
purified to homogeneity, and grown to stocks. The correct insertion of 
the EGFP gene and the absence of wild type virus in the final stocks 
were determined by Southern blot analyses. The virus was propagated and 
titrated on monolayer of Vero cells (American Type Culture Collection, 
Manassas, VA; catalogue CCL81) using standard protocols (9). Infected Vero 
cells were harvested, titrated, and stored in aliquots at -80°C until used. 
Cells and Cell lines: 
Corneal epithelial cells were isolated fronl the cornea of Balb/c mice as 
described with some modifications (10). Briefly, whole eyes were incubated at 
37°C in PBS containing 10 mM tetra sodium diaminetetracetate dehydrate 
(Sigma-Aldrich, St. Louis, MO) for 45 min. After incubation, the epithelial 
cell layer was separated from the adjacent corneal tissue by gentle teasing with 
a fine forceps. The intact epithelial layer was washed several times in PBS, 
followed by treatment with collagenase D (Roche, Basel, Switzerland) at 37°C 
for 30 min. The disrupted epithelial cells were then passed through a 40-JLm 
filter to make a single cell suspension. In some cases, the intact epithelial cell 
layer was used for the experiments. 
The cell lines used for the experiments were MKT -1 (Murine Stromal 
Fibroblast cell line) (kindly gifted by Dr Winston Kao, Department of 
Ophthalmology, University of Cincinnati, Cincinnati, OH), J774A.1 
(Macrophage cell line ) (ATCC, Cat# TIB-67). The DC 2.4 (Dendritic cell line ) 
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was generously provided by Dr. K. L. Rock (Deptt. of Pathology, University 
of Massachusettes Medical Schools, MA). 
Corneal HSV -1 infection 
Corneal infections of all mice groups were conducted under deep anesthesia 
induced by i.p. injection of avertin (Sigma-Aldrich, St. Louis, MO). Mice were 
scarified on their corneas with a 27 -gauge needle, and a 4 J!.l drop containing 
5xl05 pfu of virus was applied to the eye and gently massaged with the 
eyelids. 
Subconjunctival injection 
Subconjunctival inoculation of murine rIL-6 (BD PharMingen, San-Diego, 
CA) and anti-murine IL-6 Ab (5 J!.g/J!.l) (BD Pharmingen, Rat IgG (5J!.g/J!.I) 
(R& D Systems) and LPS (1J..tg/ml dissolved in PBS) (Sigma) was performed, 
as described previously (11). Briefly, subconjunctivalinoculations were done 
using a 2-cm 32-gauge needle and syringe (Hamilton, Reno, NV) to penetrate 
the perivascular region of conjunctiva and deliver into the subconjunctival 
space. Control mice received PBS only. 
In vitro stimulation of corneal epithelial cell layer and cell lines with IL-6 
For corneal epithelial cells, an intact corneal epithelial cell sheet was 
incubated in DMEM without sera containing various concentrations of 
recombinant IL-6 at 370 C and 5% C02 on a rotator shaker for 24 hrs. After 24 
hrs, the cell sheets were spun down and total RNA was extracted. Treatment 
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with LPS (l j.lglml) (Sigma) and DMEM only was used as positive and 
negative control. 
For various cell lines (MKT-l, J774A.l and DC 2.4), 105 cells/well 
were grown for 48 hrs in 6 well plate containing 10% FCS-DMEM. After 48 
hrs of growth the cells were finally washed and stimulated with various 
concentrations of recombinant IL-6 in serum-free DMEM for 24 hrs. 
Following stimulation, the supernatants were collected and stored in -800 C 
until used. Treatment with DMEM only was used as negative control and LPS 
(l Jlglml) (Sigma) was used as a positive control. 
Immunofluorescence staining and confocal microscopy 
For immunofluorescence staining, eyes were enucleated at 24 hr. p. i. and snap 
frozen in OCT compound (Sakura, Torrance CA). Six-micron-thick sections 
were cut, air dried, and fixed in 4% para-formaldehyde at room temperature 
for 20 min. Sections were blocked with 3% BSA-PBS containing 0.05% 
Tween 20 and 1 :200 dilution of Fc block (clone 2.4G2; BD PharMingen). Anti 
VEGF biotinylated antibody (R&D systems, Minneapolis, MN) was diluted 
(1: 100) in 1 % BSA-PBS containg 0.1 % Triton-X and incubated overnight at 
4°C. Sections were then treated with Streptavidin APC (BD Pharmingen) for 
45 min. Corneal sections were repeatedly washed in PBS and mounted with 
Vectashield mounting medium for fluorescence (Vector Laboratories Inc. 
Burlingame, CA) and visualized with a confocal microscope (Leica, Wetzlar, 
Germany). 
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For immunofluorescence staining of IL-6 stimulated J77 4A.1, the 
protocol was same except, fixation was done with Acetone-methanol (1: 1) at ­
20° C and Streptavidin Alexa-fluor (Molecular Probes, Eugene, OR) was used 
in place of Strepatividin APC. Following staining the J774A.1 cells was spun 
down on microscopic slides using a cytospin machine. Slides were mounted 
with Vectashield mounting medium for fluorescence (Vector Laboratories Inc. 
Burlingame, CA) and visualized with a confocal microscope (Leica, Wetzlar, 
Germany) 
RT-PCR 
To detect the presence of IL-6 receptors (gp80 and gp 130) on various cell 
types, total RNA from corneal epithelial cell sheet, MKT-1, J774A.1 and 
DC2.4 cells was extracted using RNeasy RNA extraction kit (Qiagen, 
Valencia, CA). Briefly, tissues were lysed in RLT buffer, and RNA was 
purified following manufacturer's instructions (Qiagen). DNase treatment 
(Qiagen) was done to remove any contaminating genomic DNA. Total RNA (1 
p,g) was reverse transcribed using murine leukemia virus reverse transcriptase 
(Life Technologies, Bethesda, MD) with oligo(dT) as primer (Invitrogen, San 
Diego, CA). All cDNA samples were ali quoted and stored at -20°C until 
further use. PCR was performed in PTC-100 Programmable Thermal 
Controller (MJ Research, Cambridge, MA) using Hot Start PCR Master Mix 
(Promega, Madison, WI). The primers used were murine GAPDH (forward: 
CATCCTGCACCACCAACTGCTTAG and reverse: 




ACTTTCGT ACTGA TCCTCGTGG); murine gp130 (forward: 





Cytokine ELISA of cell culture supernatant 
Following 24 hrs of in vitro stimulation, the supernatant was collected and 
used immediately or stored at -80°C until further use. Lysates were analyzed 
using a standard sandwich ELISA protocol. Anti-VEGF capture and 
biotinylated detection Abs and recombinant standards for murine VEGF164 
were from R&D Systems. The color reaction was developed using 2,2' -azino­
bis-3 ethylbenzthiazoline-6-sulfonic acid) (Sigma-Aldrich) and measured with 
an ELISA reader (Spectramax 340; Molecular Devices, Sunnyvale, CA) at 405 
nm. The detection limit was 2 pglrnl. Quantification was performed with 
Spectramax ELISA reader software version 1.2. 
Intracellular staining and flow cytometry 
Single cell suspensions were prepared from four corneas at 12 and 24 h post 
injection, as described elsewhere (12), with some modifications. Briefly, 
corneal buttons were incubated with collagenase D (Roche) for 60 min at 37°C 
in a humidified atmosphere at 5% C02. After incubation, corneas were 
disrupted by grinding with a syringe plunger and passing through a cell strainer. 
Cells were washed and suspended in RPMI 1640 with 10% FBS. The Fc 
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receptors on the cells were blocked with unconjugated anti-CDI6/32 (BD 
PharMingen) for 30 min. Intracellular staining of VEGF was done as 
described before (4). All samples were collected on a FACScan (BD 
Biosciences, San Diego, CA), and data were analyzed using Cell Quest 3.1 
software (BD Biosciences). 
Quantitative real-time peR 
Total RNA from four corneas per time point was extracted by using RNeasy 
RNA extraction kit (Qiagen, Valencia, CA). Briefly, tissues were lysed in RLT 
buffer, and RNA was purified following manufacturer's instructions (Qiagen). 
DNase n-eatment (Qiagen) was done to remove any contaminating genomic 
DNA. To generate cDNA, 1 /lg of total RNA was reverse transcribed using 
murine leukemia virus reverse transcriptase (Life Technologies) with 
oligo( dT) as primer (Invitrogen), according to manufacturer's instructions. All 
cDNA samples were aliquoted and stored at -20°C until further use. 
Real-time PCR was performed using a DNA Engine Opticon (MJ 
Research Inc.). PCR was performed using SYBR Green I reagent (Qiagen), 
according to manufacturer's protocoL PCR amplification of housekeeping 
gene, murine GAPDH, was done for each sample as a control for sample 
loading and to allow normalization between samples. During the optimization 
procedures of the primers, 1 % agarose gel analysis verified the amplification 
of one of the product of the predicted size with no primer-dimer bands. The 
absence of primer-dimer formation for each olignucleotide set was also 
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validated by establishing the melting curve profile. The semiquantitative 
comparison between samples was calculated as follows: the data were 
nom1alized by substracting the differences of the threshold cycles (CT) 
between the gene of interest's CT and the "house keeping" gene GAPDH's CT 
(gene of interest CT - GAPDH CT = L1 CT) for each sample. The L1 CTwas then 
compared to the expression levels of the negative control sample (sample L1 CT 
-negative control L1 CT) (negative control samples include PBS injected eyes 
in case of in vivo experiments and media only in case of in vitro experiments). 
To determine the relative enhanced expression of the gene of interest, the 
following calculation was made: fold change = 2 (-sampleLl C T negative controiLl C T) . 
The primers used for . murine VEGF164 were, forward 
GCCAGCACATAGAGAAATGAGC and reverse 
CAAGGCTCACAGTGATTTTCTGG 
Statistical analysis 
Unless specified, a one-tailed, paired Student's t-test has been used. 
RESULTS 
Uninfected resident corneal cells act as a source of VEGF at an early 
stage of viral infection 
To determine and characterize the cellular source of VEGF following virus 
infection, mice were infected with HSV -1 RE expressing EGFP under the 
control of gC promoter (HSV-1-RE-pgC-EGFP). At 24 hr p. i., corneas were 
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stained for VEGF. As demonstrated in Fig lA, it is clearly evident that 
uninfected corneal epithelial cells surrounding the infected ones stained 
positive for VEGF. However, no double staining was observed in the infected 
cells. In addition, in the single cell suspension of cornea infected with HSV-1 
RE pgC-EGFP, uninfected resident corneal cells (GFP-) and not infected cells 
(GFP+) were stained positive for VEGF at 24 hr p. i. (Fig. 1B and 1C). These 
results indicate that production of VEGF at an early time point was a product 
of uninfected resident corneal cells. 
Subconjunctival injection of recombinant murine IL-6 induces VEGF in a 
dose dependent manner 
To establish the role of IL-6 in paracrine production of VEGF, various doses 
(50ng, lOOng, 200ng and 400ng) of recombinant murine IL-6 was injected 
subconjunctivally (3 mice/group). At 24 hr post injection, an approximately an 
8-10 fold increase in the VEGF transcript level was detectable by Real Time 
PCR (Fig. 2A). In addition, a dose dependent increase in the VEGF transcript 
level also occurred following IL-6 administration (Fig. 2A). At this time point, 
the VEGF transcript level was 1.8 fold (50ng), 5.9 fold (100ng), 9.8 fold 
(200ng) and 10.1 fold (400ng) higher in comparison to the PBS control. 
Antibody neutralization of recombinant IL-6 resulted in a dose dependent 
decrease in VEGF transcript levels (Fig. 2B). In addition, at an antibody 
concentration of 500ng (3.5 fold) and 5J.1g (1.4 fold) was significantly 
decreased (p<O.05) in comparison to rat the IgG control (Fig. 2B). 
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In additional experiments, the number of resident corneal cells 
producing VEGF in response to subconjunctival injection of murine IL-6 
(200ng) was quantified. As demonstrated in Fig. 2C, 0.9 ± 0.3% and 1.5 ± 
0.2% of cells were VEGF at 12 and 24 hr post injection respectively. In 
addition antibody neutralization of IL-6 resulted in a_significant (p<O.05) 
decrease in the number of VEGF cells in comparison to the rat IgG control. 
These experiments suggest that IL-6, normally produced post HSV-1 
infection, can in itself induce the production of VEGF from resident corneal 
cells. 
To further delineate the possible cellular sources of VEGF following 
IL-6 stimulation primary corneal epithelial cells and various cell lines that 
represent cellular components of the cornea were stimu1ated in vitro with 
various doses of recombinant IL-6 for 24 hrs. All the cells investigated 
expressed both the gp80 and gp130 transcripts of the IL-6 receptor (Fig 3). 
As shown in Fig 4A and B, corneal epithelial cells and stromal 
fibroblast cells respond to recombinant murine IL-6 result in a dose dependent 
manner to express VEGF transcript and protein levels respectively. In sharp 
contrast, there was no significantjncrease in the amount of VEGF produced 
from a dendritic cell line (DC 2.4) following stimulation with IL-6 for 24 hrs 
(Fig 5B). 
To find out whether in addition to resident corneal cells, inflammatory 
cells can also produce VEGF in response to IL-6 stimulation, the macrophage 
cell line (J774A.1) was stimu1ated with various concentrations of recombinant 
murine IL-6. As evident from Fig. 5A, C, following 24hrs of stimulation, there 
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was a dose dependent increase in the VEGF label in cell culture supernatant. 
The VEGF level was significantly higher (p<O.05) than the media control. 
Intracellular staining of some of these stimulated cells revealed positive 
staining for VEGF in the cytoplasm. 
DISCUSSION 
This present study evaluates the role of IL-6 in the initiation of corneal 
angiogenesis following virus infection. Both in vivo and in vitro data indicate 
that IL-6 produced from virus infected cells can stimulate noninfected resident 
corneill cells and other inflammatory cells in a paracrine manner to secrete 
VEGF, a potent angiogenic factor. Thus, our data substantiates the close 
relationship between proinfiammatory cytokines and VEGF induced corneal 
neovasc ularization. 
In HSK, angiogenesis is a prominent and early feature of the 
pathogenesis, with VEGF mRNA detectable by 12 hr pj. and proteins 
detectable by 24 hpj. (3, 4). Interestingly only a replication competent and 
not an incompetent virus have been shown to induce VEGF expression in the 
cornea, indicating the essential role of viral replication in the corneal 
epithelium to initiate this process (13). However, the production of VEGF 
seems to be the consequence of a paracrine effect of molecules released from a 
virus infected cell, as uninfected corneal cells and not infected cells stained 
positive for VEGF. The above observations raise the question as to the 
mechanism by which HSV infection of a cell triggers another cell to turn on 
VEGF gene expression. Although productive HSV infection by virtue of virion 
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host shutoff protein eliminates most host cell protein synthesis (14), evidence 
suggests that some proinflammatory cytokine gene such as IL-l and IL-6 are 
upregulated (15, 16, 17). Supporting this scheme, previous studies 
demonstrated that shortly after HSV infection, both IL-l and IL-6 are 
abundant by day 1 post infection. (5, 6). It is presently unclear as to whether, 
during a corneal infection, one of two cytokines precedes the other or whether 
they are both produced at the same time. However, based on the generally 
accepted fact that IL-l precedes IL-6 in inflammatory cascade of events and 
our previous results (7), we believe that IL-l is a critical cytokines and is 
presumably upregulated very early after infection of the cornea and induces 
the production of IL-6 from resident corneal cells (7). However, these 
cytokines are potent stimulators of VEGF production (18, 19). Previous study 
from our group demonstrated the essential role of IL-ln in VEGF production 
from corneal epithelial cells (7). In addition, intrastromal injection of IL-6 
results in corneal neovascularization in a VEGF dependent process (20). 
Specifically, IL-6 produced from a virus infected cell can stimulate 
surrounding noninfected cells to produce VEGF. 
In our study the VEGF producers appeared to be two major cell types, 
noninflammatory residential corneal cells and inflammatory cells. Previous 
investigations have demonstrated that inflammatory cells start infiltrating 
corneal stroma 48 hr pj. onwards (21). Thus, it can be assumed that early after 
infection most VEGF producing cells were noninflammatory resident corneal 
epithelial and stromal cells. Supporting this scheme we were able to 
demonstrate that both corneal epithelium and stromal cells can produce VEGF 
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in response to IL-6. The second VEGF-producing cell type was inflammatory 
cells in the corneal stroma. These were the major VEGF producers in the 
clinical phase, with both PMN and macrophage-like cells involved. Since virus 
is usually undetectable in the stroma and is absent in the cornea after the first 
few days of infection, virus itself, would seem not to be the stimulus for 
VEGF production. As macrophages are seen in the clinical phase, our data 
along with other findings (4) indicate that the predominant producer cell type 
appeared to be noninflammatory cells in the preclinical phase, but 
subsequently, in the clinical phase, macrophages and probably stromal 
fibroblast in the stroma were the sites of VEGF production. In addition, 
neutrophils also contribute significantly to VEGF induced angiogenesis 
process by carrying preformed VEGF in their vesicles (22, 23). However, it is 
not known whether IL-6 influence the neutrophil degranulation process and 
thereby causing release of preformed VEGF. This issue is currently under 
investigation. 
Taken together, this study support the hypothesis that cytokines 
induced as a consequence of viral replication play an essential role in VEGF 
induced corneal neovascularization process. An important component of this 
cytokine milieu, as demonstrated in this present report is IL-6. Our results 
indicate that the control of angiogenesis by limiting the virus induced 
inflammatory response represents a useful therapy of herpetic ocular disease, 
an important cause of human blindness. 
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Fig 1. Uninfected and not infected corneal epithelial cells express VEGF 
following ocular infection with HSV-1 following 24 hr post infection 
A. Mice were infected with HSV-l-RE-pgC-GFP. At 24 hr p. i. eyes were 
frozen in OCT compound and six micron sections were made. The slides were 
stained with monoclonal anti mouse biotinylated VEGF antibody and 
Streptavidin APC. The slides were visualized under a confocal laser scanning 
microscope (Leica, Wetzlar, Germany). Original bar 80f..1m. The single arrow 
indicates the HSV -1 RE gC-GFP infected corneal epithelial cells and the 
double arrow indicates VEGF cells. Epi: Epithelium; Str: Stroma 
B. Mice were infected with HSV-l-RE-pgC-GFP. At 24 hr p. i. corneas were 
digested and single cell suspension was made as described in Materials and 
Methods. The cells were stained with monoclonal anti mouse biotinylated 
VEGF antibody and Streptavidin APC. The slides were visualized under a 
confocal laser scanning microscope (Leica, Wetzlar, Germany). Original bar 
80f..1m. The single arrow indicates the HSV -1-RE-pgC-GFP infected resident 
corneal cells and the double arrow indicates VEGF cells. 
C. At 24 hr p. i. single cell suspensions were made from HSV -1-RE-pgC-GFP 
infected corneas. Numbers of cells expressing GFP (virus infected) out of total 
VEGF cells were enumerated by FACS analysis. The dot plot represents one 
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Fig 2. Subconjunctival injection ofrecombinant murine IL-6 stimulates 
resident corneal cells to produce VEGF 
A. At 24 hr post injection four corneas/group were processed for the extraction 
of cellular total RNA. Real-time PCR analysis was conducted to detect the 
VEGF mRNA expression in corneas of mice injected with different doses of 
recombinant IL-6 as described in Materials and Methods. LPS (lJlg/ml) was 
injected subconjuctivally as positive control. Results are shown as mean ± SD 
of three separate experiments. * Significant difference in comparison to PBS 
control. 
B. For antibody neutralization of IL-6, 200ng of recombinant murine IL-6 was 
mixed with various doses of anti IL-:-6 antibody and injected subconjunctivally. 
At 24 hr post injection four corneas/group were processed for the extraction of 
cellular mRNA. Real-time PCR analysis was conducted to quantify the VEGF 
mRNA in corneas of mice injected with different doses of recombinant IL-6 as 
described in Materials and Methods. Results are shown as mean ± SD of three 
separate experiments. "'Significant differences in comparison to rat IgG 
control. 
C. At 24 hr post injection 6 corneas/ group were collected and made into 
single cell suspension. The cells were counted and intracellular staining was 
done with anti murine biotinylated VEGF antibody and streptavidin PE. The 
number of VEGF+ cells was enumerated by FACS analysis. The dot plot 
represents one of the three separate experiments. The number in the right hand 
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Fig 3. Unmanipulated corneal epithelial cells, MKT-l, DC2.4 and J774A.l 
cell lines express transcripts for functional IL-6 receptor 
Total RNA was extracted and was converted into cDNA, as described in 
Materials and Methods. PCR was performed in PTC-100 Programmable 
Thermal Controller (MJ Research). Murine GAPDH served as internal control. 
Lane M: molecular weight marker. 
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Fig 4. lnterleukin 6 stimulation of corneal epithelial cells and stromal 
fibroblast result in the expression of VEGF transcript and protein 
respectively 
A. Murine corneal epithelial cell sheet was isolated from naIve mice as 
described in Materials and Methods. The epithelial cell sheets were then 
placed in DMEM without sera containing various concentrations of 
recombinant murine IL-6 for 24 hrs at 37° C. After incubation total RNA was 
extracted and converted to CDNA. Real-time PCR analysis was conducted to 
detect the VEGF mRNA expression in corneal epithelial cells stimulated with 
different doses of recombinant IL-6 as described in Materials and Methods. 
Results are shown as mean ± SD of three separate experiments. * Significant 
increase in comparison to media control. 
B. Stromal fibroblast cell line (MKT-1) was stimulated with various doses of 
murine recombinant IL-6 for 24 hrs. After incubation the supernatant was 
collected and amount of VEGF protein in the supernatant was estimated using 
a sandwich ELISA as outlined in Materials and Methods. LPS (lJlglml) was 
used as positive control. Results are expressed as mean ± SD of three separate 
experiments. * Significant increase in comparison to media control. The 
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Fig 5. Macrophage cell line (J774A.l) produces VEGF following in vitro 
stimulation with various doses ofrecombinant murine IL-6 
A. Macrophage cell line (J774A.1) was stimulated with various doses of 
murine recombinant IL-6 for 24 hrs. After incubation the supernatant was 
collected and amount of VEGF protein in the supernatant was estimated using 
a sandwich ELISA as outlined in Materials and Methods. LPS (1~glml) was 
used as positive control. Results are expressed as mean ± SD of three separate 
experiments. * Significant increase in comparison to media control. The 
horizontal line represents the constitutive production of VEGF (media 
control). 
B. Dendritic cell line (PC2.4) was stimulated with various doses of murine 
recombinant IL-6 for 24 hrs. After incubation the supernatant was collected 
and amount of VEGF protein in the supernatant was estimated using a 
sandwich ELISA as outlined in Materials and Methods. LPS (1 ~glml) was 
used as positive control. Results are expressed as mean ± SD of three separate 
experiments. 
C. Macrophage cell line (J774A.1) was stimulated with 200ng of murine 
recombinant IL-6 for 24 hrs. Following incubation intracellular staining was 
done to detect the VEGF using anti murine biotinylated VEGF antibody and 
streptavidin Alexa-flour. A total volume of 100~1 cell suspension containing 
5x104 cells was spun down using a cytospin. The slides were visualized under 
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Research described in this chapter is a slightly modified version of an article 
submitted for publication in The Journal of Immunology by Partha Sarathi 
Biswas, Kaustuv Banerjee, Bumseok Kim, Paul R. Kinchington and Barry T. 
Rouse. 
In this chapter "we" and "our" refers to co-authors and me. My contributions 
in the paper include (1) selection of the topic (2) data analysis and 
interpretation (3) planning experiments (4) compiling and interpretation of the 
literature (5) understanding how results fit with the literature (7) compilation 
of contributions into one paper (8) providing structure to the paper (9) making 
graphs, figures and tables (10) writing and editing. 
ABSTRACT 
Ocular infection with Herpes simplex virus (HSV) results in a blinding 
immuno-inflammatory lesion known as herpetic stromal keratitis (SK). Early 
preclinical events include PMN infiltration and neovascularization in the 
corneal stroma. In this report, we demonstrate that HSV infection of the 
cornea results in the upregulation of the Cycloxygenase 2 enzyme (COX-2). 
The likely source of COX-2, at least initially after infection, was stromal 
fibroblasts. This enzyme was shown to contribute to the early inflammatory 
and neovascularization process in response to HSV infection through 
upregulation of prostanoids. Inhibition of COX-2 with a selective inhibitor 
was shown to reduce corneal angiogenesis and HSK severity. The 
administration of a COX-2 inhibitor resulted compromised PMN infiltration 
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into the cornea. In addition, the treatment diminished corneal vascular 
endothelial growth factor levels, likely accounting for the reduced angiogenic 
response. Since early pro inflammatory events and angiogenesis appears to 
represent a critical step in the pathogenesis of SK, these results indicate that 
targeting COX-2 for inhibition should prove useful for the therapy of herpetic 
SK. 
INTRODUCTION 
Herpetic stromal keratitis (HSK) is a blinding immunopathological reaction 
that results from ocular infection with Herpes simplex virus 1 (HSV -1) (1). 
This results mainly froJ;Il a chronic inflammatory reaction in the normally 
transparent and avascular cornea. Studies with the murine model have 
revealed a complicated pathogenesis, the critical event being the influx of 
CD4+ T cells (2, 3). Prior to the T cell-mediated immunoinflammatory phase, 
multiple events occur after virus infection that set the stage for the subsequent 
pathology. These events include the production of proinflammatory mediators, 
prominent invasion of the cornea by polymorphonuclear leukocytes (PMN) 
and corneal angiogenesis (4). However the factors responsible to initiate the 
inflammatory and angiogenic events in the corneal stroma following virus 
infection remain poorly understood. Previous studies demonstrated that HSV 
replication, which in the mouse model is usually confined to the corneal 
epithelium, results in the production of proinflammatory cytokines and 
chemokines, creating an environment favorable for cell influx and 




inflammatory mediators that determine the subsequent outcome of this 
immunopathological condition is crucial for designing potential therapeutic 
approaches to counteract this blinding disease in humans. 
Arachidonic acid (AA), an unsaturated fatty acid is a normal 
constituent of membrane phospholipids and is released by the actions of 
phospholipase A2. AA is converted to prostaglandins (PGs) by cycloxygenase 
(COX) and to leukotrienes (LTs) by 5-lipoxygenase metabolites that are 
biologically very active and modulate cellular functions (5). The two isoforms 
of COX, COX-l and COX-2 are encoded by two separate genes and exhibit 
distinct cell specific expression, regulation and subcellular localization (5). 
COX-l is a constitutive enzyme and is essential for various physiological 
functions (5). In contrast, COX-2 is an inducible enzyme that is induced in a 
variety of cell types by diverse stimuli (5). COX-2 induced production of 
prostanoids is often implicated in chronic inflammatory diseases, 
characterized by edema, chemotactic factors, prostanoids, leukotrienes and 
phospholipase (6, 7). Increased COX-2 induced synthesis of prostaglandins 
stimulates cancer cell proliferation (8), promotes angiogenesis (9, 10), inhibits 
apoptosis (11) and increases metastatic potential (12). In addition, recent 
studies demonstrated the essential role of COX-2 mediated up regulation of 
prostanoids in various ocular inflammatory models (13-15). 
The aim of this study was to determine whether inhibition of COX-2, 
as could be achieved by using a selective COX-2 blocker, had an effect on SK 
pathogenesis. Our results with ocular infection with HSV demonstrate that 
selective inhibition of COX-2, but not COX-I, resulted in significantly milder 
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disease and reduced corneal angiogenesis compared to control mice. This 
difference in disease phenotype was an indirect event and was shown to be the 
consequence of a compromised early inflammatory response. Taken together, 
our results demonstrate that COX-2 mediated prostanoids production is critical 
in SK pathogenesis, and that the use of NSAIDs to inhibit COX-2 represents a 
valuable approach for disease control. 
MATERIALS AND METHODS 
Mice 
Wild-type, female, 6 to 8 week old, Balb/c and C57BU6 mice were purchased 
from Harlan Sprague-D~wley (Indianapolis, IN). Animals were sex- and age­
matched for all experiments. Mice transgenic (Tg) for IL-l ra protein (T14 
hemizygous line) were kindly provided by Dr. David Hirsh (Department of 
Biochemistry and Molecular Biophysics, College of Physician and Surgeons, 
Columbia University, New York, NY). All manipulations involving the 
immunocompromised mice were performed in a laminar flow hood. All 
experimental procedures were in complete agreement with the Association for 
Research in Vision and Ophthalmology resolution on the use of animals in 
research. 
Virus 
HSV-l RE (obtained from Dr. Robert Hendricks Laboratory, University of 
Pittsburgh School of Medicine, PA) was used in the present study. HSV-l RE­
pgC-GFP was derived in the RE strain background of HSV -1, detailed by 
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Hendricks group (16) and is a null mutant at the gC locus. For construction, a 
cloned Pstl-EcoRI fragment (sequences from 95811 to 96789 in wild type 
HSV-1 genome) containing the gC promoter and first part of the gC open 
reading frame (ORF) in the corresponding sites of puc8, was first collapsed by 
digestion, blunt end generation and religation to remove Pstl, HindIII and sites 
between. A NheI-XbalI fragment derived from pEGFP-N1 (Clontech, Palo 
Alto, CA) was then inserted into the unique NheI site located at the sequence 
encoding residue 6 of gC, resulting in an in-frame placement of the EGFP 
gene immediately following the glycoprotein C first 6 residues and gC 
promoter. This plasmid was linearized, co-transfected with purified HSV -1 RE 
DNA into vero cells using calcium phosphate coprecipitation, and progeny 
virus with EGFP driven by the native gC 
promoter were identified by fluorescence, plaque purified and insert confirmed 
by Southern blot analysis. The virus was propagated and titrated on a 
monolayer of Vero cells (American Type Culture Collection, Manassas, VA, 
Cat. No. CCL81) using standard protocols (17). Infected Vero cells were 
harvested, titrated, and stored in aliquots at -80DC until used. 
Corneal HSV-1 infection 
Mice were ocularly infected with HSV-1 RE (5x105 pfu for Balb/c and 5x106 
pfu for C57BL6) under deep anesthesia induced by intraperitoneal injection of 
A vertin (Sigma-Aldrich, St. Louis, MO). Mice were lightly scarified on their 
corneas with a 27-gauge needle, and a 4-pJ drop containing the required dose 
of virus was applied to the eye and gently massaged with the eyelids. 
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Clinical observations and angiogenesis scoring 
The eyes were examined on different days post infection (p. i.) by a slit-lamp 
biomicroscope (Kowa Co., Nagoya, Japan), and the clinical severity of 
keratitis of individually scored mice was recorded as described previously (18). 
Briefly, the clinical lesion score of SK was described as 0, normal cornea; 1, 
mild haze; 2, moderate haze, iris visible; 3, severe haze, iris not visible; 4, 
severe haze and corneal ulcer; and 5, corneal rupture. Angiogenesis severity 
was measured as described previously (19). According to this system, a grade 
of 4 for a given quadrant of the circle represents a centripetal growth of 1.5 
mm toward the corneal center. The score of the four quadrants of the eye was 
then summed to derive the neovessel index (range, 0-16) for each eye at a 
given time-point. 
Administration of COX-l and COX-2 inhibitors 
For COX inhibition experiments, Balblc and C57BL6 mice were treated with 
COX-1 inhibitor SC-560 (10 mg/kg/day) (Upjohns and Pharmacia, a division 
of Pfizer) and COX-2 inhibitor SC-236 (10 mg/kg/day) (Upjohns and 
Pharmacia, a division of Pfizer) or vehicle 0.5% methylcellulose, 0.025% 
Tween 80 (Sigma) by gavages. The treatment was started a day before corneal 
infection and continued till day lOp. i. These doses were recommended by the 
manufacturer as being selective for effective inhibition of COX-1 and COX-2 
and have been used previously (20,21). 
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In vitro stimulation of murine stromal fibroblast cell line with various 

recombinant murine cytokines 

For stimulation of murine stromal fibroblast cell line (MKT -1) (kindly 

provided by Dr. W. Kao, Department of Ophthalmology, University of 

Cincinnati, Cincinnati, OR), 105 cells/well were grown for 48 hrs in 6 well 

plate containing 10% FCS-DMEM. After 48 hrs of growth the cells were 

finally washed and stimulated with various concentrations of recombinant IL-

la, IL-1~, TNF-a, IL-6, IL-18, IFN-y, IL-2 and VEGF in sera free DMEM for 

24 hrs. Following stimulation, total RNA was extracted and stored at -800 C 





Corneal micropocket assay 

The murine corneal micropocket assay was done as described previously (22). 

Various doses (50ng and 200ng) of recombinant mutine IL-1~ (R&D systems) 

were added to these pellets before insertion into corneal pockets (four eyes per 

group). In some experiments, mice were treated with COX-2 inhibitors before 

corneal micropocket assay was performed. Angiogenesis was quantitated at 






For histopathological analysis, eyes were extirpated at day 20 pj. and fixed in 
10% buffered neutral formalin. Staining was performed with hematoxylin and 
eosin (H&E; Richard Allen Scientific, Kalamazoo, MI). 
Immunofluorescence and Immunohistochemistry staining 
For immunofluorescence staining of Gr-l + cells, at day 2 p. i., eyes were 
frozen in optimum cutting temperature (OCT) compound (Miles, Elkart, IN). 
Sections were stained for Gr-l + cells with fluorescein isothiocyanate (FITC)­
labeled anti-mouse Gr-l+ antibody (clone RB6-8C5, BD PharMingen) and 
counterstained with Vectashield mounting medium for fluorescence with 
propidium iodide (Vector Laboratories, Burlingame, CA) and visualized under 
a fluorescence microscope (Leica, Wetzlar, Germany). 
For immunohistochemistry eyes were enucleated at the indicated time 
points and snap frozen in OCT compound (Miles, Elkart, IN). Six-micron­
thick sections were cut, air dried, and fixed in acetone:methanol (1: 1) at -20°C 
for 10 min. Endogenous peroxidase activity was blocked using a 500/0 alcohol 
solution containing 0.3% hydrogen peroxide for 15 min, and sections were 
blocked with 3% BSA-PBS. For detection of COX-2, Goat Anti-Cox2 (M-19) 
(Santa Cruz Biotechnology, Santa Cruz, CA) was diluted 11100 and incubated 
for 1 hr at room temparature. Sections were then treated with Rabbit Anti-Goat 
IgG biotinylated antibody (1/200) (Vector Laboratories, Burlingame, CA) 
followed by HRP-conjugated streptavidin for 45 min (111000 dilution; Jackson 
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ImmunoResearch Laboratories, West Grove, PA) and 3, 3'-diaminobenzidine 
substrate (Biogenex, San Ramon, CA), and counterstained with hematoxylin 
(Richard Allen Scientific, Kalamazoo, MI). Irrelevant biotinylated antibody 
was used as negative controls. 
Enzyme-linked immunosorbent assay (ELISA) of corneal lysate 
For preparation of corneal lysates, six corneas per time-point were pooled and 
processed as described previously (24). Lysates were analyzed using a 
standard sandwich ELISA protocoL Anti-IL-6 capture and biotinylated 
detection antibodies were from BD PharMingen (clone MP5-20F3), and 
standard recombinant murine (rm)IL-6 was from R&D Systems (Minneapolis, 
MN). Anti-IL-la., anti-MIP-2, anti-VEGF, anti IL-l~ and anti TNF-a. capture, 
biotinylated detection antibodies and recombinant standards were from R&D 
Systems. The color reaction was developed. using 2,2'-azinobis(3­
ethylbenzothiazoline-6-sulfonic acid diammonium salt) (Sigma-Aldrich) and 
measured with an ELISA reader (Spectramax 340, Molecular Devices, 
Sunnyvale, CA) at 405 nm. Quantification was performed with Spectramax 
ELISA reader software version 1.2. 
Prostaglandin E2 extraction and quantification was done as per 
manufacturer's protocoL Briefly, six corneas per time point were dissected 
under a microscope, dipped briefly in 100 11M indomethacin in saline to stop 
prostaglandin synthesis and wash off excess blood, and placed in a 
homogenizer tube containing garnet beads, and 0.5 ml of ethanol. The corneas 
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were homogenized using a tissue homogenizer (PRO Scientific Inc., Monroe, 
CT). Protein precipitate was pelleted in a microcentrifuge, and the ethanol 
layer was removed to a clean tube. The ethanol was evaporated by vacuum 
centrifugation, the residue was redissolved in enzyme immunoassay (EIA) 
buffer (Cayman Chemical, Ann Arbor, MI), and samples were analyzed for 
PGE2 and LTB4 using an EIA kit (Cayman Chemical). 
Flow cytometry 
Single cell suspensions were prepared from four corneas at 48 h post infection, 
as described elsewhere (25). The Fc receptors on the cells were blocked with 
unconjugated anti-CD16/32 (BD PharMingen) for 30 min. Samples were 
incubated with FITC-Iabeled anti-Gr-1 Ab (clone RB6-8C5; BD PharMingen) 
and isotype controls for 30 min. All samples were collected on a FACScan 
(BD Biosciences, San Diego, CA), and data were analyzed using Cell Quest 3.1 
software (BD Biosciences). 
Reverse transcriptase Polymerase chain reaction 
Total RNA from MKT-1 cells was extracted by using Tri-reagent (Molecular 
Biology, Cincinnati, OR). Total RNA (l Jlg) was reverse transcribed using 
murine leukemia virus reverse transcriptase (Life Technologies, Bethesda, 
MD) with oligo(dT) as primer (Invitrogen, San Diego, CA). All cDNA 
samples were aliquoted and stored at -20°C until further use. PCR was 
performed in PTC-100 Programmable Thermal Controller (MJ Research, 
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Cambridge, MA) using Hot Start PCR Master Mix (Promega, Madison, WI). 
The primers used were murine GAPDH Forward 
CATCCTGCACCACCAACTGCTTAG, Reverse 
GCCTGCTTCACCACCTTCTTGATG; murine IL-1~ Forward 
CAACCAACAAGTGATAT, Reverse GATCCAGAGTCTCCAGCTGCA; 
murine COX-2 Forward TTCGGGAGCACAACAGAGTG; Reverse 
TAACCGCTCAGGTGTTGCAC. 
Quantitative real-time peR 
Total RNA from four corneas per time point was extracted by using RNeasy 
RNA extraction kit (Qiagen, Valencia, CA) according to manufacturer's 
instructions. To generate cDNA, 1 Jlg of total RNA was reverse transcribed 
using murine leukemia virus reverse transcriptase (Life Technologies) with 
oligo(dT) as primer (Invitrogen), according to manufacturer's instructions. All 
cDNA samples were aliquoted and stored at -20°C un"til further use. 
Real-time PCR was performed using a DNA Engine Opticon (M] 
Research Inc.). PCR was performed using SYBR Green I reagent (Qiagen), 
according to manufacturer's protocol. PCR amplification of housekeeping 
gene, murine GAPDH, was done for each sample as a control for sample 
loading and to allow nornlalization between samples. During the optimization 
procedures of the primers, 1 % agarose gel analysis verified the amplification 
of one of the product of the predicted size with no primer-dimer bands. The 




validated by establishing the melting curve profile. The semiquantitative 
comparison between samples was calculated as follows: the data were 
normalized by substracting the differences of the threshold cycles (CT) 
between the gene of interest's CTand the "house keeping" gene GAPDH's CT 
(gene of interest CT- GAPDH CT = L1 CT) for each sample. The L1 CT was then 
compared to the expression levels of the vector control sample (sample L1 CT­
vector L1 CT). To determine the relative enhanced expression of the gene of 
interest, the following calculation was made: fold change = 2 (-sampleLl C T - vectorLl 
T The primers used were murine GAPDH Forward 
CATCCTGCACCACCAACTGCTTAG, Reverse 
GCCTGCTTCACCACCTTCTTGATG; HSV polymerase Forward 
CCGTACATGTCGATGTTCACC, Reverse 
ATCAACTTCGACTGGCCCTTC; HSV gB Forward: 
CGTTTCGCAGGTGTGGTTC, Reverse: ATGTCGGTCTCGTGGTGC. 
murine COX-2 Forward TTCGGGAGCACAACAGAGTG; Reverse 
TAACCGCTCAGGTGTTGCAC; murine COX-1 Forward ACT CAC TCA 
GTT TGT TGA GTC ATT C, Reverse TTT GAT TAG TAC TGT AGG GTT 
AATG. 
Statistical analysis 





Mice treated with COX-2 inhibitor demonstrated diminished SK severity 
and corneal angiogenesis following ocular HSV -1 infection 
Mice (Balb/c and C57BL6) were ocularly infected with HSV -1 RE and at 
different days post infection and corneal levels of COX-I, COX-2 mRNA and 
PGE2 protein were measured by Real Time PCR and ELISA respectively. As 
demonstrated in Fig. 1, the kinetic study revealed a steady increase in the 
COX-2 mRNA and PGE2 protein levels during the preclinical phase (till day 7 
p. i.) of SK. The levels of COX-2 mRNA and PGE2 protein were below the 
limit of detection in naIve corneas. However, COX-I mRNA was found to be 
constitutively expressed in naIve corneas and following HSV infection no 
significant (p<0.05) increase in the expression level was observed (data not 
shown). Taken together these data indicate that corneal intlammation during 
the preclinical phase is associated with a prompt. increase in the COX-2 
expression, an enzyme essential for the synthesis of various prointlammatory 
prostanoids such as PGE2. 
To elucidate the essential role of COX-2 in HSK pathogenesis, three 
groups of Balb/c (5xI05 pfu) and C57BL6 (5x106 pfu) mice were treated (till 
day 10 p. i.) with COX-2 inhibitor (SC-260), COX-I inhibitor (SC-536) or 
vehicle respectively. These mice were evaluated clinically for the development 
of SK following ocular HSV -IRE infection over a 20 days test period. As 
shown in Fig. 2A and 2C, groups of Balb/c and C57BL6 mice receiving COX­
2 inhibitor demonstrated significantly (p< 0.05) reduced SK severity [mean 
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score 1.4 ± 0.7 (Balb/c) and 1.0 ± 0.8(C57BL6)] in comparison to COX-1 
[mean score 2.9 ± 0.8 (Balb/c) and 2.8 ± 0.9 (C57BL6)] and vehicle control 
[mean score 3.4 ± 0.6 (Balb/c) and 2.7 ± 0.9 (C57BL6)] groups. In addition, 
while 87.5% (Balb/c) and 62.5% (C57BL6) eyes demonstrated clinically 
evident lesions (score 3 or more), only 25% (Balb/c) and 12.5% (C57BL6) 
COX-2 inhibitor treated eyes developed such lesions (Fig. 2B and D). 
Attempts to infect mice with a higher virus dose resulted in lethality, but still 
few developed a SK score of greater than or equal to 3 in COX-2 inhibitor 
treated mice (data not shown). Histopathological analysis of representative 
eyes of vehicle and COX-1 inhibitor treated mice revealed severe 
inflammatory changes at;ld cellular infiltration in the corneal stroma at day 20 
p. i. (Fig 2E). However, in mice, treated with COX-2 inhibitor protein, only 
mild, inflammatory changes and cellular infiltrations were evident (Fig 2E). 
In concurrence with lesion incidence and severity, significant 
differences were apparent in the average extent of angiogenesis in mice treated 
with COX-2 inhibitor and vehicle only following ocular infection with HSV-1 
RE (5x105 pfu for Balb/c and 5x106 pfu for C57BL6) at day 20 p. i. (Fig 3B 
and D). At day 20 p. i., 10 of 16 eyes (Balb/c) and 8 of 16 eyes (C57BL6) of 
vehicle treated mice had developed an angiogenesis score of greater than 10 
(Fig.3A and C). In marked contrast, no eyes of COX-2 inhibitor treated 
BALB/c and C57BL6 mice developed equivalent scores (Fig. 3A and C). 
When the overall angiogenesis was compared in the groups of vehicle treated 
and COX-2 inhibitor treated mice (Baible and C57BL6), vehicle control mice 
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showed 3-4 times (day 20 p. i.) more angiogenesis than COX-2 inhibitor 
treated mice (Fig. 3A and C). 
IL-l~ induces COX-2 expression in murine cornea following ocular HSV­
1 infection 
To evaluate the cellular source of COX-2 at an early stage of virus infection, 
Balb/c corneas were infected with HSV-l-pgC-GFP. After 24hr p. i., corneas 
were isolated and GFP+ (infected) and GFP- (uninfected) corneal cells were 
sorted by FACS and analyzed for COX-2 mRNA expression by Real Time 
PCR analysis. Interestingly, uninfected corneal cells expressed significantly 
(p< 0.05) higher COX-2 InRNA in comparison to infected cells (Fig 4A). 
Polymerase chain reaction of GFP- (uninfected) corneal cells revealed 3000­
4000 fold lesser viral mRNA (gB, tk) in comparison to GFP+ (infected) at this 
time point (data not shown). In addition, by immunohistochemically we were 
able to demonstrate that corneal stromal fibroblasts and few corneal epithelial 
cells expressed COX-2 at 24 hr p. i. (Fig 4B). 
Additional experiments were carried out to detect the factors 
responsible for inducing COX-2 expression in corneal stromal fibroblasts 
following viral infection. Based on previous findings, potential candidates for 
inducing COX-2 were proinfiammatory cytokines. Thus a murine stromal 
fibroblast cell line was stimulated in vitro by various doses of 
proinfiammatory cytokines known to be upregulated in murine corneas 
following HSV infection (lL-la, IL-l~, TNF-a, IL-6, IL-18, IFN-y, IL-2 and 
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VEGF). Interestingly, only IL-1~ (in all the doses used) and TNF-a (only at 
the highest dose used) induced COX-2 mRNA expression at 24 hr p. i. as 
revealed by RT- PCR (data not shown). Quantitatively, Real Time PCR 
analysis revealed a significant (p<O.05) and dose dependent increase in COX­
2 mRNA expression in IL-1~ treated cells (Fig. 5A). Hence, IL-1~ produced 
as consequence of corneal HSV infection (Fig. 5B) may serve as a potential 
molecule to induce COX-2 and drive the early inflammatory process. 
Supporting this notion, we were able to demonstrate that administration of IL­
l ~ in the murine cornea by micropocket assay resulted in a significant 
(p<O.05) and dose dependent increase in COX-2 mRNA level (Fig 5C). 
Blocking of IL-1 ~ activity using IL-1 receptor antagonist transgenic mice 
resulted in a significantly (p<O.05) diminished COX-2 mRNA and PGE2 
levels in murine cornea following ocular HSV -1 infection (Fig 5D and E). 
Diminished inflammatory response in mice treated with COX-2 inhibitor 
during the preclinical phase of HSK 
Normally, after corneal HSV -1 infection, PMN infiltrate the corneal stroma at 
48 hr p. i. (26). However, in mice treated with COX-2 inhibitor and eventually 
showing a reduction in SK severity, the influx of PMN was severely 
compromised (Fig 6). As revealed by FACS analysis at 48 hr p. L, there was 
approximately 5-6 fold reduction in the number of PMN in COX-2 treated 
corneas in comparison to vehicle controls. (Fig 6). 
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We reasoned that the scarce cellular influx in the treated group was a 
result of a block in the induction of proinflammtory cytokines and 
chemokines, as a consequence of impaired COX-2 activity. As demonstrated 
in Fig 7, indeed there was a significant reduction (p< 0.05) in IL-6, IL-la, 
MIP-2 and PGE2 levels during the preclinical phase. However no significant 
difference was observed in IL-l ~ and TNF-a levels at these time points (data 
not shown). Although the LTB4 level was reduced at day 1 p. i., there was no 
significant (p< 0.05) reduction at 3 and 7 days p. i. (data not shown). 
Compromised angiogenic response following ocular HSV infection in 
COX-2 inhibitor treated mice 
As stated above, groups of mice treated with COX-2 inhibitor showed 
diminished angiogenic responses in comparison to vehicle treated controls. 
These mice when tested for corneal VEGF level during the preclinical phase, 
demonstrated significantly (p< 0.05) reduced levels 9f VEGF at 3 and 7 days 
p. i. in comparison to vehicle controls (Fig 8A). Previous studies in tumor 
systems demonstrated that IL-l ~ can induce VEGF production through 
upregulation of COX-2 and prostanoids (27). To demonstrate the angiogenic 
activity of COX-2 induced protanoids in murine corneas, different doses of 
murine rIL-l~ were administered by corneal micropocket assay, and the extent 
of angiogenesis was measured at day 3 post implantation. Interestingly, IL-l ~ 
induced a dose-dependent angiogenic response (Fig. 8B). In such eyes, COX-2 
protein was readily detectable by immunohistochemistry around the pellet 
containing recombinant IL-l ~ protein (200ng) in corneal stroma at day 4 post 
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implantation (Fig BC). In addition, IL-l ~ (200ng) implanted eyes 
demonstrated a significant (p< 0.05) increase in the corneal PGE2 and VEGF 
protein levels in comparison to pellet only at this time point (Fig. BE). 
Administration of COX-2 inhibitor in those mice resulted in a significant 
(p<O.05) decrease in the angiogenic response (Fig BD). This decrease in 
angiogenic response was associated with a reduction in corneal PGE2 and 
VEGF protein levels in those corneas (Fig BE). 
DISCUSSION 
This study focuses on the early events in the pathogenesis of the blinding 
immunoinflammatory le~ion SK caused by ocular infection with HSV. In this 
report, we demonstrate that HSV infection of the cornea results in the 
upregulation of the COX-2 enzyme. This enzyme was shown to contribute to 
the inflammatory and neovascularization process in the corneal stroma 
through upregulation of prostanoids. The likely source of COX-2, at least 
initially after infection was corneal stromal fibroblasts. Interleukin-1 fj, a 
proinflammatory cytokine produced as a consequence of HSV replication 
stimulates stromal fibroblasts to produce COX-2. The present study 
demonstrates for the first time, the critical role of COX-2 for herpetic SK 
lesion development. Accordingly, selective inhibition of COX-2 and not 
COX-l results in significantly milder disease and reduced corneal 
angiogenesis compared to control mice. This difference in disease phenotype 
was an indirect event and was shown to be the consequence of a compromised 






plays an important role in early inflammatory phase and blocking COX-2 
activity using NSAIDS could represent a valuable therapeutic approach to 
control HSK. 
Early after ocular HSV infection the cellular source of COX-2 was 
shown to be the stromal fibroblasts. It is not clear how COX-2 expression is 
induced in stromal fibroblasts following HSV replication, since the infection 
appears confined to the corneal epithelium (4). Our study demonstrated that 
IL-1~, and too some extent TNF-a, produced as a consequence of HSV 
replication, may stimulate stromal fibroblasts to produce COX-2. Blocking IL­
1~ by IL-1 receptor antagonist protein resulted in a diminished COX-2 
expression. This study, as well as others (28-30), indicated that IL-1~ 
stimulated fibroblasts are potent producers of COX-2. The above observations 
thus delineate the mechanism by which HSV infection of a cell triggers 
another cell to turn on COX-2 gene expression. However previous studies 
revealed that virus reactivation in the trigeminal ganglion is associated with 
upregulation of COX-2 transcript expression (31). Thus it is unclear whether 
upregulation of COX-2 is also mediated by some HSV-encoded components 
released from infected cells. We are currently analyzing the role of some of 
these viral encoded proteins as candidates to explain COX-2 triggering. 
A prominent early event after virus infection of the cornea is the influx 
of inflammatory cells into the avascular stroma, primarily PMN (26). This 
influx occurs promptly after infection and most likely serves several functions. 
These include antiviral effects (26, 32) and an involvement in 
neovascularization (33). Our result showed that mice treated with selective 
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COX-2 inhibitor have compromised neutrophil influx. This observation is in 
concordance with previous findings demonstrating the essential role of COX-2 
induced prostanoids in neutrophil influx and activation in various 
inflammatory models such as rheumatoid arthritis, dermatitis, periodonititis 
and pancreatitis (34-36). How COX-2 induced prostanoids in infected mice 
cornea causes PMN influx remains unclear. 
The possible signals responsible for the PMN influx are most likely 
multiple and nonviral derived. Previous observations demonstrated that MIP-2, 
IL-6 and IL-l are critical in early influx of PMN in the murine cornea 
following virus infection (24, 37, 38) and the level of COX-2 correlates with 
the expression patterns of these cytokines and chemokines (39). Thus, it is 
highly likely that COX-2 induced prostanoid synthesis aid PMN influx 
through upregulation of IL-l, IL-6 and MIP-2. Supporting this scheme, we 
could show that mice treated with selective COX-2 inhibitors and having 
compromised neutrophil influx had lower levels of corneal IL-l, IL-6 and 
MIP-2. Previous observations demonstrated that in humans selective inhibition 
of COX-2 can prevent IL-8 mediated PMN chemotaxis at the inflammatory 
site (40). This observation along with ours further strengthens the notion that 
COX-2 plays a critical role in PMN chemotaxis by upregulating various 
proinflammtory cytokines and chemokines. In addition, PMN and 
macrophages themselves serve as an additional source of COX-2 induced 
prostanoids at the inflammatory site (41, 42). We anticipate that, early after 
infection, COX-2 produced from stromal fibroblasts facilitates the influx of 
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PMN, which in tum now acts as an additional source of prostanoids, thus 
setting the stage for the chronic immuno-inflammatory phase. 
Early PMN invasion contributes to corneal pathology because the cells 
are a major source of angiogenesis factors (33, 43) and perhaps also tissue 
damaging factors such as NO (44). Thus, in line with the mininlal early PMN 
response noted in COX-2 inhibitor treated mice, such animals showed a 
marked reduction in angiogenesis. One factor derived from PMN, as well as 
from other cell types involved in neovascularization, is VEGF (43). We 
demonstrated that VEGF was significantly down-regulated in COX-2 inhibitor 
treated mice in comparison to control animals. This observation is in accord 
with previous findings in rheumatoid synoviocyte and tumour models (9, 10). 
How COX-2 induces VEGF production is not known. One explanation for 
diminished angiogenic response in COX-2 inhibitor treated mice is, COX-2 
induced PGE2 itself has been shown to be proangiogenic (45). PGE2 along 
with other prostanoids can stimulate the production of VEGF (39). However, 
it is not clear whether this effect is direct or mediated by upregulation of other 
cytokines such as IL-6, IL-l and chemokines containing E-L-R motifs. We are 
currently testing such notions in our HSV angiogenesis model. 
COX-2 represents a logical target for therapy, since this component 
acts as a principal inflammatory and angiogenic factor in HSV induced 
corneal inflammation. However, COX-2 inhibitors should be used with a word 
of caution. Previous studies in Endotoxin induced uveitis (EIU) model 
suggested that disturbance of the AA pathway exacerbates EID in COX-2­
deficient mice (46) . This was caused by elevated LTB4 and 5-LO metabolized 
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from arachidonic acid via the lipoxygenase pathway. At least, in our system 
we were able to demonstrate that inhibition of COX-2 is not associated with 
an increase in LTB4, thus justifying our approach in counteracting corneal 
immunoinflammatory lesion with COX-2 inhibitors. 
Taken together, our results support the hypothesis that the 
inflammatory milieu and angiogenic stimuli created early after infection play 
an important role in HSV -induced ocular lesions. An important participant of 
this environment is COX-2 induced prostanoid synthesis. Blocking the effect 
of COX-2 by a specific COX-2 inhibitor abrogates the cascade of events that 
culminate in HSK. This regulation is indirectly mediated by down-regulating 
various signaling molecules previously known to be important in HSK 
pathogenesis and corneal angiogenesis. Thus targeting COX-2 could prove to 
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Fig 1. Kinetics ofCOX-2 mRNA and PGE2 leveis in HSV-l infected corneas 
ofBalh/c and C57BL6 mice 
A. 	 At 1, 3, and 7 days postinfection, four corneas/group were processed 
for the extraction of cellular mRNA. Real-time PCR analysis was 
conducted to detect the COX-2 mRNA expression in corneas of mice 
infected HSV-1 , as described in Materials and Methods. Results are 
shown as mean ± SD of three separate experiments. 
B. 	 Levels of PGE2 were estimated from corneas (6 corneas/ time point) 
of mice infected with HSV-1 RE by a competitive ELISA, as 
outlined in Materials and Methods. Results are expressed as mean ± 
SD of three separate experiments (6 corneas/time point). 
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Fig 2. Mice receiving COX-2 inhibitors show reduced HSK severity 
A. 	 Mean lesion HSK score at day 20 p. i. of mice infected with 5 x 105 
PFU (Balb/c) HSV-1 RE. Each dot represents the HSK score from one 
eye. Horizontal bars and figures in the parentheses indicate the mean 
for each group. 
B. 	 Bar diagram demonstrates the percentage severity of each group of 
Balb/c mice infected with 5x105 pfu at day 20 p. i. Figure in the 
parenthesis represents the percentage of eyes showing HSK score 
greater than or equal to 3. 
C. 	 Mean lesion HSK score at day 20 pj. of mice infected with 5 X 106 
PFU (C57BL6) HSV -1 RE. Each dot represents the HSK score from 
one eye. Horizontal bars and figures in the parentheses indicate the 
mean for each group. 
D. 	 Bar diagram demonstrates the percentage severity of each group of 
C57BL6 mice infected with 5x106 pfu at day 20 p. i. Figure in the 
parenthesis represents the percentage of eyes showing HSK score 
greater than or equal to 3. 
E. 	 Mice (Balb/c) were infected with 5 x 105 pfu HSV-1 RE. Mice were 
terminated at day 20 pj., and eyes were processed for paraffin 











5C 	 E 
a'·.·. 	 e .' ••..a0000 
•u l 880 00 
(3.4±0.6) (2 .9±O.8) ~ (2.7±O.9) (2.8±O.9) 
......_-- 4 •••• 00 
rn•• 00 * 2 o 0 00 (l .4.!:D.7) 0:I: •••• 
't:P&O •• 
0000 
Vehide 	 COX-I COX-2 Vehide 
inhibi1lDr inhibiiDr inhibiiDr inhibiiDr COX-l inhibitar 
(62.5~.) (62 .5~.) 
COX-2 inhibitar 
Vehide COX-I COX-2 
inhibimr inhibiiDr inhibiiDrirIIIiIIitt 
.------------ Day2Dp.i -----------+ 
162 

Fig 3. Mice receiving COX-2 inhibitor show diminished angiogenic response 
following HSV-l infection at day 20 p. i. 
A. 	 Angiogenesis scores for individual eyes of different groups of Balb/c 
mice infected with 5 x 105 PFU HSV-1 RE at day 20 pj. Horizontal 
bars and figures show the mean for each group. 
B. 	 At day 20 pj., extensive growth of blood vessels can be seen in Balb/c 
mice receiving vehicle or COX-1 inhibitor and infected with 5 x 105 
PFU HSV-l RE. Mice receiving COX-2 inhibitor show minimum 
angiogenic sprouts near the limbal ring with the same dose. 
C. 	 Angiogenesis scores for individual eyes of different groups of C57BL6 
mice infected with 5 x 106 PFU HSV-1 RE at day 20 pj. Horizontal 
bars and figures show the mean for each group. 
D. 	 At day 20 pj., extensive growth of blood vessels can be seen in 
C57BL6 mice receiving vehicle or COX-1 inhibitor and infected with 
5 x 105 PFU HSV-1 RE. Mice receiving COX-2 inhibitor show 
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Fig 4. Uninfected stromal fibroblasts are the major producers of COX-2 
following ocular HSV-J infection. 
A. 	 Mice (Balb/c) were infected with 5xl05 PFU HSV-l-RE- pgC-GFP. 
At 24 hr p. i. corneas, GFP+ cells (infected) were sorted out from 
GFP- cells (uninfected) and total RNA was extracted. Real-time PCR 
analysis was conducted to detect the COX-2 mRNA expression in 
corneas of mice infected HSV-1, as described in Materials and 
Methods. Results are shown as mean ± SD of three separate 
experiments. *, Statistically significant differences (p < 0.05) in 
comparison to GFP+. 
B. 	 Immunohistochemistry for COX-2 expression in corneas of Balb/c 
mice. (arrows) are detectable in corneal stroma of Balb/c mice 
infected with high, 5 x 105 PFU HSV-1 RE at day 1 poi. 
Diaminobenzidine was used as substrate, and sections were 
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Fig S. IL-1P induced COX-2 expression in murine stromal fibroblast cell 
line. 
A. Murine stromal fibroblast cells were stimulated with different doses 
of murine rIL-l (3 for 24 hr. After 24 hr post stimulation cells were 
collected and total RNA was extracted. Real-time PCR analysis was 
conducted to detect the COX-2 mRNA expression in corneas of mice 
infected with HSV-l, as described in Materials and Methods. Results 
are shown as mean ± SD of three separate experiments. *, 
Statistically significant differences (p < 0.05) in comparison media 
controL 
B. 	 Mice (Balb/c) ~ere infected with 5xl05 PFU HSV-l-RE. At different 
days p. i. 4 corneas/time point were taken and total RNA was 
extracted. Reverse transcriptase was conducted to detect the IL-l (3 
mRNA expression in corneas of mice infected with HSV-1, as 
described in Materials and Methods. 
C. 	 Different concentrations of rIL-l(3 (50, 200 ng) were administered in 
Balb/c corneas (n = 8) by corneal micropocket assay. Real-time PCR 
analysis was conducted at day 1 p. i. to detect the COX-2 mRNA 
expression in corneas of mice infected HSV-1, as described in 
Materials and Methods. Results expressed as mean ± SD. 
Statistically significant differences (p < 0.05) in comparison to only 
pellet. 
D. Control C57BL6 mice and IL-l ra Tg mice were infected with 5xl06 
pfu HSV-1 RE. At 1, 3, and 7 days postinfection, four corneas/group 
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were processed for the extraction of cellular mRNA. Real-time PCR 
analysis was conducted to detect the COX-2 mRNA expression in 
corneas of mice infected HSV-1, as described in Materials and 
Methods. Results are shown as mean ± SD of three separate 
experiments. ., Statistically significant differences (p < 0.05) in 
comparison to control animals. 
E. 	 Control C57BL6 mice and IL-1 ra Tg mice were infected with 5x106 
pfu HSV -1 RE. At 1, 3, and 7 days p. i., levels of PGE2 were 
estimated from corneas (6 corneas! time point) of mice infected with 
HSV-1 RE by a competitive ELISA, as outlined in Materials and 
Methods. Results are expressed as mean ± SD of three separate 
experiments (6 corneas/time point). ., Statistically significant 
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Fig 6. Reduced PMN influx in COX-2 inhibitor treated mice at 48 hr. p. i. 
Single-cell suspensions of corneal cells were prepared from four eyes 
at 48 h p. i. The cells were counted and stained with FITC-Iabeled anti 
Or-I antibody, and numbers of Or-I-positive cells were enumerated by 
fluorescein-activated cell sorter (FACS). Dot-plot is representative of 
one of three separate experiments. The number on the upper-right 
comer represents the percentage of Or-I+ cells of total corneal cells at 
48 h p. i. 
At 48hr p. i. frozen sections (61l) of Balb!c mice cornea were stained 
for PMN with FITC labeled Gr-I antibody as described in Materials 
and Methods. Counterstaining was done with Propidium Iodide. 
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Fig 7. Reduced levels of Cytokines and Prostanoids in the cornea of COX-2 
inhibitor treated mice 
At indicated time-points, six corneas/group were processed for 
measuring the IL-6, IL-1a., MIP-2 and PGE2levels. Levels of IL-6, IL-
la., MIP-2 and PGE2 were estimated from supernatants of corneal 
lysates of mice infected with 5 x 105 pfu HSV -1 RE by an antibody 
capture ELISA, as outlined in Materials and Methods. Results are 
expressed as Mean ± SD of three separate experiments (six 
corneas/time-point). * Statistically significant differences in 
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Fig 8. Compromised angiogenic responses in COX-2 inhibitor treated mice 
A. 	 At indicated time-points, six corneas/group were processed for 
measuring the VEGF level. Level of VEGF was estimated from 
supernatants of corneal lysates of mice infected with 5 x 105 pfu 
HSV-1 RE by an antibody capture ELISA, as outlined in Materials 
and Methods. Results are expressed as Mean ± SD of three separate 
experiments (six corneas/time-point). *, Statistically significant 
differences in comparison to vehicle control. 
B. 	 Different doses of recombinant murine IL-1 ~ was implanted in 
corneal stroma by micropocket assay and extent of angiogenesis was 
measured at day 3 post implantation as described in Materials and 
Methods. *, Statistically significant differences in comparison to 
pellet only. 
C. 	 Recombinant murine IL-1 ~ (200ng) was implanted in corneal stroma 
by micropocket assay and at day 3 post implantation frozen sections 
(6Jl) of those implanted corneas were made. These sections were 
stained for COX -2 by immunohistochemistry as described in 
Materials and Methods. Diaminobenzidine was used as substrate, 
and sections were counterstained with hematoxylin. Original 
magnification x200. 
D. 	 Reconlbinant mOline IL-1 ~ (20Ong) was implanted in corneal stroma 
of COX-2 inhibitor treated and vehicle control mice by micropocket 
assay. At day 3 post implantation extent of angiogenesis was 
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measured as described in Materials and Methods. *, Statistically 
significant differences in comparison to vehicle control. 
E. 	 Recombinant murine IL-l p(200ng) was implanted in corneal stroma 
of COX-2 inhibitor treated and vehicle control mice by micropocket 
assay. At day 3 post implantation 6 corneas/group was processed for 
measuring the VEGF and PGE2 level. Results are expressed as Mean 
± SD of two separate experiments (6 corneas/time-point). * **, 
Statistically significant differences in comparison to vehicle control 
and COX-2 inhibitor treated group. 
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Research described in this chapter is a slightly modified version of an article 
published in 2004 in Journal of Leukocyte Biology by Partha Sarathi Biswas, 
Kaustuv Banerjee, Mei Zheng and Barry T. Rouse. 
Biswas, P. S., K. Banerjee, M. Zheng, and B. T. Rouse. 2004. Counteracting 
corneal immunoinflammatory lesion with interleukin-l receptor antagonist 
protein. J Leukoc BioI. 76(4):868. Copyright 2004. The American Association 
of Immunologists, Inc. 
In this chapter "we" and "our" refers to co-authors and me. My contributions 
in the paper include (1) selection of the topic (2) data analysis and 
interpretation (3) planning experiments (4) compiling and interpretation of the 
literature (5) understanding how results fit with the literature (7) compilation 
of contributions into one paper (8) providing structure to the paper (9) making 
graphs, figures and tables (10) writing and editing. 
ABSTRACT 
Herpetic Stromal Keratitis (HSK) is a T cell orchestrated 
immunointlammatory lesion that results from corneal HSV infection. Previous 
reports indicate an essential role for proinflammatory cytokine IL-l in HSK 
pathogenesis. The present study evaluates the efficacy of IL-l receptor 
antagonist (lL-l ra) protein in the management of HSK. Mice receiving IL-l 
ra had diminished disease sevelity. The administration of IL-l ra was shown 
to reduce the influx into the cornea of cells of both the innate and adaptive 
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immune response. In addition, the treatment also diminished corneal VEGF 
levels resulting reduced angiogenic response. Our results show the importance 
of targeting early proinflammatory molecules such as IL-l to counteract HSK 
and advocate IL-l ra as an effective agent to achieve this. 
INTRODUCTION 
In almost 20% of individuals with a Herpes simplex virus (HSV) infection a 
blinding immunoinflammmatory lesion, called herpetic stromal keratitis 
(HSK), develops (1). Management of HSK usually requires indefinite 
corticosteroid therapy (2). In some cases corneal damage results in permanent 
loss of vision necessitating transplantation. Studies with the murine model 
have revealed a complicated pathogenesis, the critical event being the influx of 
CD4+ T cells (3, 4). Leading to the influx of these crucial cells are several 
events that include proinflammatory cytokine and chemokine production, 
influx of innate immune cells and angiogenesis (5-7). Both IL-l and IL-6 are 
likely the mediators of corneal inflammation (8-10), and have been recently 
demonstrated as essential in the pathogenesis of corneal disease following 
HSV-1 infection (11). 
To test our hypothesis that IL-l represents one of the first mediators to 
initiate the inflammatory cascade, we blocked its activity using the IL-l 
receptor antagonist protein (IL-l ra). The IL-l ra protein is a naturally 
occurring isoform of IL-l and can bind to IL-l receptors with high-affinity but 
fails to induce signal transduction (12). The protein is routinely used in 
treatment of human immunoinflammatory conditions such as rheumatoid 
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arthritis (13). Interleukin -1 receptor antagonist protein administered 
systemically down regulates cytokine production in humans and rats (14-16). 
In the ocular alkali bum murine model, IL-l ra has been shown to have a 
therapeutic potential (16). We show using a combination of systemic and local 
IL-l ra administration, that the severity of corneal angiogenesis and HSK is 
diminished following ocular HSV infection. This was a consequence of a 
down regulation of various inflammatory mediators, normally induced by IL-l 
in HSV infected corneas. Thus blocking IL-l activity using IL-l ra protein 
could represent a valuable therapeutic approach in managing HSK. 
MATERIALS AND METHODS 
Mice 
Wild type female 6 to 8 weeks old C57BU6 mice were purchased from Harlan 
Sprague-Dawley (Indianapolis, Indiana). Animals were sex and age matched 
for all experiments. Mice transgenic for IL-l receptor antagonist protein (T14 
hemizygous line) were kindly provided by Dr. David Hirsh (Department of 
Biochemistry and Molecular Biophysics, College of Physician and Surgeons, 
Columbia University), All manipulations involving the immunocompromized 
mice were performed in a laminar flow hood. All experimental procedures 
were in complete agreement with the Association for Research in Vision and 




HSV-1 RE (obtained from Dr. Robert Hendricks Laboratory, University of 
Pittsburgh School of Medicine) was used in the present study. The virus was 
propagated and titrated on monolayer of Vero cells (ATCC, Cat No. CCL81) 
using standard protocols (17). Infected Vero cells were harvested, titrated and 
stored in aliquots at _80 
0 
C until used. 
Corneal HSV ..1 infection 
Mice were ocularly infected with HSV -1 RE under deep anesthesia induced by 
intraperitoneal injection of Avertin (Sigma-Aldrich, St. Louis, MO). Mice 
were lightly scarified on their corneas with a 27-gauge needle and a 4J.tl drop 
containing the required dose of virus was applied to the eye and gently 
massaged with the eyelids. 
Clinical observations and Angiogenesis Scoring 
The eyes were examined on different days post infection by a slit-lamp 
biomicroscope (Kowa Co. Nagoya, Japan), and the clinical severity of keratitis 
of individually scored mice was recorded as described before (11). 
Angiogenesis severity was measured as described previously (18). Briefly, a 
grade of 4 for a given quadrant of the circle represents a centripetal growth of 
1.5mm toward the corneal center. The score of the 4 quadrants of the eye were 





Subconjunctival inoculation of recombinant human IL-l ra protein 
[0.5mg/cornea, Img/cornea] (supplied by Amgen Inc., Thousand Oaks, CA) 
was performed as described previously (8). Briefly, subconjunctival 
inoculations were done using a 2 em 32 gauge needle and syringe (Hamilton, 
Reno, NV) to penetrate the perivascular region of conjunctiva and required 
dose of IL-l ra protein was delivered into the subconjunctival space. Control 
mice received 0.2% sodium hyaluronate in PBS only. Mice received 
recombinant human IL-l ra one day before corneal infection with HSV -1. 
Alzet infusion pump implantation 
Alzet osnl0tic punlps (Palo Alto, CA) were used to deliver IL-l ra 
subcutaneously as described before (19). Briefly, the micro-osmotic pumps 
(Model 1007D) were implanted 24 hr before ocular infection. The pumps were 
loaded with IL-l ra or vehicle as per the manufacturer's instructions under 
sterile condition. The mice were weighed, marked and anaesthetized using 
Isoflurane (Abbott Laboratories, North Chicago, IL). Mice were placed into 
dorsal recumbancy, clipped over the shoulder area and prepared for the 
surgery. A small 1 em incision was made caudal to the shoulder area, the skin 
was undermined with a hemostat and then the pump was placed into the 
prepared pocket. Skin was then closed with 9 mm autoclips (Braintree 
Scientific Inc., Braintree, MA). The pump was taken out after 7 days and the 
skin was closed again with 9mm clips. With a mean pumping rate of 0.5flllhr 
(mean fill volume of IOOfll), calculated drug infusion rates were 5mg/kg 
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b.wtlhr for 7days, 2.Smglkg b.wtlhr for 7days and Imglkg b.wtlhr for 7days. 
Control mice received osmotic pumps with vehicle only for the same period of 
time. 
Histopatholgy 
For histopathological analysis, eyes were extirpated at day 20 p. i. and fixed in 
10% buffered neutral formalin. Staining was performed with Hematoxylin and 
Eosin (Richard Allen Scientific, Kalamazoo, MI). 
Immunofluorescence staining 
For immunofluorescence staining, at day 20 p. i. eyes were frozen in optimum 
cutting temperature (OCT) compound (Miles, Elkart, IN). Six micron thick 
sections were cut, air dried and fixed in acetone for 20 minutes at 40 C. The 
sections were blocked with 3% BSA (Sigma) containing unconjugated anti 
CD16/32 (1 :200) antibody (BD Pharmingen, San Diego, CA) for 3 hours at 
370 C. For detection of CD4+ T cells, the sections were incubated with FITC 
labeled anti mouse CD4+ antibody (Clone RM4-S, Pharmingen) in 1 % BSA at 
40 C overnight. Sections were repeatedly washed in PBS and mounted with 
Vectashield mounting medium for fluorescence with Propidium Iodide 
(Vector Laboratories Inc. Burlingame, CA) and visualized under a microscope 




Single-cell suspensions were prepared from 4 corneas at different days post 
infection as described elsewhere (20), with some modifications. Briefly, 
corneal buttons were incubated with collagenase D (Roche, Mannheim, 
Gennany) for 60 min at 37°C in a humidified atmosphere at 5% CO2. After 
incubation, eyes were disrupted by grinding with a syringe plunger and 
passing through a cell strainer. Cells were washed and suspended in RPMI 
1640 with 10% PBS. Blocking was done with unconjugated anti-CD16/32 
(Phanningen) for 30 min. Samples were incubated with FITC labeled anti Gr­
1 antibody (Clone RB6-8C5, Phanningen), FITC labeled anti CD4 antibody 
(Clone RM4-5, Phanningen) and isotype controls for 30 minutes. All samples 
were collected on a FACScan (BD Biosciences, San Diego, CA), and data 
were analyzed using CellQuest 3.1 software (BD Biosciences). 
Cytokine ELISA of corneal lysate 
For preparation of corneal lysates, 6 corneas per time point were pooled and 
minced. All procedures were done on an ice bath. Minced pieces were 
collected in 1ml DMEM without FCS and homogenized using a tissue 
homogenizer (PRO Scientific Inc., Monroe, CT) four times, 15 seconds each, 
with a gap of 1 minute between homogenization to allow the sample to cool. 
The lysate was then clarified by centrifugation at 14,000 rpm for 5 minute at 
4 
D 
C. The supernatant was collected and used immediately or stored at _80 
D 
C 
until further use. Lysates were analyzed using a standard sandwich ELISA 
protocol. Anti IL-6 capture and biotinylated detection antibodies were from 
184 

Pharmingen (Clone MP5-20F3) and standard recombinant murine IL-6 was 

from R&D Systems Inc, Minneapolis. Anti MIP-2 and anti VEGFl64 capture 

and biotinylated detection antibodies and recombinant standards for murine 

MIP-2 and murine VEGFl64 were from R&D Systems. For detection of 

recombinant human IL-l ra, anti human IL-l ra capture and detection antibody 

and recombinant human IL-l ra were obtained from R&D Systems Inc. 

Minneapolis. The color reaction was developed using ABTS (Sigma) and 

measured with an ELISA reader (Spectramax 340, Molecular Devices, 

Sunnyvale, CA) at 405nm. Quantification was performed with Spectramax 





Unless specified a standard student's t test has been utilized. 

RESULTS 
Subconjunctival administration of IL-l ra protein has no effect on HSK 
severity and corneal angiogenesis 
To evaluate whether local administration of IL-l ra protein modulates HSK 
severity and corneal angiogenesis following ocular HSV infection, three 
groups of mice were subconjunctivally injected with 0.5mg/cornea, 
Img/cornea and vehicle only, 24 hour before corneal infection. At day 3, 5 and 
7 days post injection corneal levels of recombinant IL-l ra protein was 




detectable in both the treated groups at day 3 post injection only. However, 
levels of IL-l ra protein were undetectable at 5 and 7 days post infection. 
Mice receiving subconjunctival injection of 0.5mg/cornea, 
mg/cornea of IL-l ra protein and vehicle were assessed clinically for the 
development ofHSK following HSV-l RE (5xl06 pfu) ocular infection over a 
20 days test period. Mice transgenic for the IL-l ra protein were used as a 
positive control. As shown in Fig 2A, there was no difference in the severity 
of HSK in both treated and vehicle control mice [mean scores 2.9 ± 1.0 
(0.5mg/cornea), 2.8 ± 1.2 (lmg/cornea) and 2.9 ± 1.1 (vehicle)]. In sharp 
contrast, mice transgenic for IL-l ra protein demonstrated markedly reduced 
HSK severity (mean score of 1.3 ± 0.9) (Fig. 2A). Further, whereas treated and 
control groups showed clinically evident lesions (HSK score of 3 or more) in 
56.3% (0.5 mg/c ornea) , 50% (lmg/cornea) and 62.5% (vehicle control) of 
eyes, only 18.9% of IL-I ra Tg eyes developed lesions (Fig 2B). 
Histopathological analysis of representative eyes of. both treated and control 
C57BU6 mice revealed severe inflammatory changes and cellular infiltration 
in the corneal stroma at day 20 p. i. (Fig. 2C). However, in mice transgenic 
for IL-I ra protein only mild inflammatory changes and cellular infiltrations 
were evident (Fig. 2C). 
No significant difference (p< 0.05) was observed in the extent of 
angiogenesis between IL-l ra treated and control mice (Fig. 3A and C). 
However, mice transgenic for IL-l ra protein showed significantly (p<0.05) 
reduced corneal neovascularization in comparison to treated and control 
groups (Fig. 3A and C). By day 20 p. i, an angiogenesis score of 10 or greater 
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was observed in 8 of 16 vehicle control eyes, and in eyes receiving 
Img/cornea and O.5mg/cornea. Only 2 of 16 eyes of IL-I ra Tg mice 
developed such a score (Fig 3B). Taken together, these results indicate that 
administering IL-I ra protein locally has no effect in modulating either 
angiogenesis or keratitis. 
A combination of systemic and subconjunctival IL-l ra administration 
diminishes HSK severity and corneal angiogenesis 
A reason for the inability of subconjunctival administration in modulating 
HSK severity may be attributed to the short persistence of IL-I ra in the 
cornea. To achieve biologically active concentrations for a sustained period in 
the corneal microenvironment, different doses of IL-I ra recombinant protein 
were administered systemically via subcutaneous osmotic pump implantation 
for 7 days. In addition, mice also received a subconjunctival injection 
(lmg/cornea) (the highest concentration that could be achieved by 
subconjunctival injection). With this approach the IL-I ra protein was 
detectable in the cornea by ELISA till day 7 post injection (last time point 
analyzed) (Fig 4). In addition, serum levels of the protein in treated mice were 
significantly higher than vehicle treated animals (data not shown). 
Four groups of mice were injected with 5mg/kg body wt. Ihr for 7 days 
Sic + Img/cornea local (Group 1), 2.5mg/ kg body wt. Ihr for 7days Sic + 
Img/cornea local (Group 2), Img/ kg body wt. Ihr for 7days Sic + Img/cornea 
local (Group 3) of IL-I ra and vehicle control (Group 4) respectively. Twenty­
four hours later mice were ocularly infected with 5xI06 pfu HSV-I RE. Mice 
187 

transgenic for IL-l ra protein were used as positive control. These mice were 
evaluated clinically for the development of HSK following HSV-l (5xl06 pfu) 
corneal infection over a 20 days test period. As shown in Fig 5A, the severity 
of HSK in Groups 1 and 2 was significantly diminished (mean score of 1.3 ± 
0.9 and 1.4 ± 1.0 respectively) in comparison to Group 4 (mean score 2.9 ± 
1.1). The severity in former groups was almost similar to the IL-l ra Tg mice 
(mean score 1.2 ± 1.1). However, the severity of HSK in Group 3 and Group 4 
were similar (mean score 2.5 ± 1.1 and 2.9 ± 1.1 respectively) (Fig 5A). In 
addition, whereas the incidence of disease was 56.3% of Group 4, it was only 
25% of Groups 1 and 2 and 20% of IL-l Ra Tg mice (Fig 5B). Increasing the 
virus dose in the transgenic animals made no difference to HSK scores (data 
not shown). Histopathological analysis of representative eyes of Groups 1 and 
2 and IL-l ra Tg mice revealed mild inflammatory changes in the corneal 
stroma at day 20 p. i. In contrast, vehicle treated eyes developed more severe 
inflammatory changes (Fig. 5C). 
The extent of angiogenesis was significantly (p<0.05) lower in Group 
1, Group 2 and IL-l ra Tg mice compared to vehicle treated mice (Fig 6A and 
C). At day 20 p. i., while an angiogenesis score of 10 or greater was observed 
in 11 of 16 vehicle control eyes, only 3 of 16 eyes in Groups 1 and 2 
developed similar angiogenesis (Fig 6B). In conclusion, these results indicate 
that the protein is effective only when its concentration is maintained for at 
least 6-7 days after HSV -1 infection. 
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Reduction in the immuno-inflammatory response post IL-! ra treatment 
Normally, after a corneal HSV -1 infection, PMN infiltrate the corneal stroma 
within 6hrs, with peak numbers at 24-48 hrs (5). However, in mice treated 
with IL-l ra and eventually showing a reduction in HSK severity the influx of 
PMN was severely compromised (Fig. 7). Thus in eyes from Group 2, PMN 
numbers, as judged by Gr-l staining and flow cytometry was significantly 
lower at day 2 p. i. than in vehicle control (Group 4) (3.1 ± 0.8 % compared to 
21.5 ± 4.3 %) (based on previous observation we have used Group 2 for 
subsequent studies). In addition, at day 20 p. i. there were very few CD4+ T 
cells in the cornea of IL-l ra treated mice (12.4 ± 2.3 % of total lymphocytes). 
In sharp contrast, at day. 20 p. i. vehicle control mice had an abundance of 
CD4+ T cells (64 ± 7.5 % of total lymphocytes) as judged by FACS analysis 
and immunofluorescence staining (Fig 8A and B). 
We reasoned that the scarce cellular influx in the treated group was a 
result of a block in the induction of downstream events, as a consequence of 
impaired IL-l activity. The prime candidates include both IL-6 and MIP-2 (8, 
9). Treatment with IL-l ra (Group 2) led to a significant (p<0.05) decrease in 
the corneal IL-6 protein levels at day 5 and 7 days p. i. and MIP-2 at day 2 and 
5 days p. i. in comparison to vehicle control (Fig 9A and B). However, no 
significant difference was observed in the protein levels of IL-ln or IL-l~ 
(data not shown). 
As mentioned above, mice treated with 2.5mgl kg body wt. flu for 
7days SIc + Imglcornea local IL-l ra protein developed significantly 





Endothelial Growth Factor (VEGF) is one of the key players of corneal 
neovascularization following ocular HSV infection (21). To determine 
VEGF levels in these treated mice, we measured corneal VEGF protein levels 
at different days post infection. As expected, VEGF protein levels were 
significantly (p<O.Ol) reduced in IL-1 ra treated mice at day 5 and 7 days p. i 
in comparison to vehicle control (Fig 9C). Thus the reduction in the severity of 
HSK seen with IL-1 ra treatment was attributable to a suppression of the 
inflammatory environment, the reduction in influx of cells of the immune 
system and the reduction of VEGF, a consequence of which was diminished 
angiogenesis. 
DISCUSSION 
Using a mouse model, we have evaluated the potential of the IL-1 ra protein in 
ameliorating an HSV -1 induced immuno-inflammatory corneal lesion HSK. 
This study yields two important findings. First,. that blocking individual 
inflammatory molecules during the early stages of corneal HSV infection 
represents an alternative and effective approach to managing HSK. Second, 
the IL-1 ra protein, routinely used for the treatment of other immuno­
inflammatory human diseases (13), appears to be effective in ameliorating 
HSK lesions. Our results also confirm the importance of the cytokine IL-1 in 
the pathogenesis of HSK (11). 
Both molecular and cellular events involved in HSK pathogenesis were 
down regulated as a result of the IL-1 ra treatment. Blocking the IL-1 activity 
resulted in a block to the induction of downstream events and thereby altered 
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the environment normally conducive for the migration of inflammatory cells. 
Interleukin 1, produced from HSV infected cells (22), helps in the induction of 
other key cytokines such as IL-6 (23), also shown to be critical in the 
pathogenesis following ocular HSV infection (23). Linked with this process is 
also the production of chemokines such as IL-8 and MIP-2 (9, 16, 24), thought 
to be involved in the margination and extravasation of neutrophils at the 
corneal limbus. These events occur promptly following infection of the 
corneal epithelium and facilitating neutrophil influx (5). In addition an 
autocrine IL-l feedback loop is possibly involved in tissue remodeling in the 
cornea through the induction of IL-8 (16). Interfering with these loops 
therefore can alter the overall response following HSV -1 infection and prevent 
tissue injury. 
In the HSV infected mouse cornea peak numbers of neutrophils are 
attained within 2 days after infection (5). Due to lack of chemotactic signals 
resulting from the disruption of the normal IL-l signaling neutrophils failed to 
attain peak numbers. These results are consistent with previous findings (8, 9) 
including the most recent study conducted with IL-l ra Tg mice (11). It is 
clearly evident that neutrophils are the critical early cellular mediators of HSK 
pathogenesis, being involved in viral clearance (5, 6) and possibly tissue 
damage through the release of factors such as nitric oxide (25)or remodeling 
factors such as matrix metalloproteinases (MMPs) (26). In addition, 
neutrophils have also been considered as a source of molecules facilitating 







(27) respectively, and thereby, contributes significantly to the 
neovascularization process. 
Many other cell types can be a potential source of angiogenic factors in 
the cornea. These include the stromal fibroblast themselves; epithelial cells 
and inflammatory cells such as macrophages (21). Possibly, with disease 
progression, there is a shift in the source of angiogenic factors. In addition, 
apart from VEGF (21), other angiogenic factors such as bFGF (our 
unpublished results) or C-X-C chemokines such as MIP-2 (28) may be 
involved in HSV induced corneal angiogenesis. The possibilities are 
innumerable and presently unclear. Whatever the scenario, our results indicate 
the effectiveness of IL-1 ra in blocking the overall angiogenesis process. 
Similar results have been obtained in other murine models of corneal 
angiogenesis (29). 
The chronic inflammatory environment is maintained by the 
angiogenic response, allowing further delivery of inflammatory cells. The 
development of HSK lesions is dependent on this response, as shown in 
studies that have targeted the corneal neovascular response early after virus 
infection (7). One cell type crucial to HSK pathogenesis and presumably 
delivered by newly formed (and therefore leaky) blood vessels is the CD4+ T 
cell (3). Thus mice lacking CD4+ T cells, but possessing other components 
normally required in pathogenesis, fail to develop HSK (3, 4). Consistent with 
these reports, the lack of blood vessel development in the cornea of IL-1 ra 
treated mice prevented the influx of CD4 + T cells. Thus part of the anti­
inflammatory effects observed with IL-1 ra therapy also involved the 
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impairment in the CD4+ T cell response. Hence, IL-I ra treatment targeted at 
the early preclinical events also influenced subsequent clinical episodes in 
HSK pathogenesis. 
Finally and most importantly, results indicate that the activity of IL-I 
needs to be kept under continuous check to achieve significant results. The 
levels of IL-I in the cornea after an HSV infection remains elevated till around 
day 9 p. i. (10). Thus the protocol aimed at abrogating IL-I activity for an 
extended period of time produced the best results. Thus our results imply that 
neutralizing the inflammatory milieu at an early time point may prove 
beneficial in reducing the severity of HSK. This could be achieved by 
blocking IL-I using IL-I receptor antagonist protein. Antagonizing the 
proinflammatory environment abrogates the cascade of events that culminate 
in HSK. Thus, targeting IL-I ra protein proved to be a worthwhile therapeutic 
approach for successful management of HSK, a blinding 
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immunohistochemical study using monoclonal antibodies. Graefes 









Fig 1. Following Subconjunctival injection, presence of IL-1 ra was 
detectable in cornea for short period oftime. 
At indicated time points, 6 corneas / group were processed for measuring 
the human recombinant IL-I ra protein levels. Level of human 
recombinant IL-I ra was estimated from supernatants of corneal lysates 
of mice infected with 5xl06 pfu HSV-I RE by an antibody capture 
ELISA as outlined in materials and methods. Results are expressed as 
Mean ± SD of three separate experiments (6 corneas/time point). 
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Figure 2: No difference in HSK score between locally administered IL-l ra 
treated mice and vehicle control mice. 
A. Interleukin-l receptor antagonist protein was administered 
subconjunctivally 24 hr before corneal infection. Mean lesion HSK 
score at day 20 p. i. of mice infected with 5xl06 pfu HSV-I RE. Each 
dot represents the HSK score from one eye. Horizontal bars and 
figures in the parenthesis indicate the Mean ± SD for each group. 
Data is compiled from two separate experiments consisting of 8 eyes 
in each group. * Statistically significant differences in mean HSK 
score (p< 0.05) were observed between IL-I Ra Tg mice to either 
vehicle control ~nd IL-I ra treated eyes. 
B. Percentage severity of HSK score at day 20 p. i. of mice infected 
with 5xl06 pfu HSV-I RE. Each vertical bar represents number of 
eyes showing clinically evident lesions (HSK score~ 3). Data is 
compiled from two separate experiments consisting of 8 eyes in each 
group. 
C. Mice were infected with 5xl06 pfu HSV-l RE. Mice were 
terminated at day 20 p. i. and eyes were processed for paraffin 
embedding. Hematoxylin and Eosin staining was carried out on 6J.! 
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Fig 3. Mice treated with IL-J ra protein locally demonstrated similar 
angiogenic response like vehicle control. 
A. Interleukin-1 receptor antagonist protein was administered 
subconjunctivally 24 hr before corneal infection Kinetics of corneal 
neovascularization process in mice infected with 5x106 pfu HSV-1 RE. 
Angiogenesis scores were recorded as mentioned in the Materials and 
Methods at indicated time points. Data is compiled from two separate 
experiments involving 8 eyes per group and is expressed as Mean ± SD. 
·Statistically significant differences in angiogenesis score (p< 0.05) were 
observed between IL-1 Ra Tg mice to either vehicle control and IL-1 ra 
treated eyes. 
B. Angiogenesis scores for individual eyes of IL-1 ra treated , vehicle 
control and IL-1 ra Tg mice infected with 5x106 pfu HSV-1 RE at day 20 
p. i. Horizontal bars and figures show the mean for each group. Data are 
compiled from two separate experiments consisting of 8 eyes per group. 
C. At day 20 p. i. extensive growth of blood vessels can be seen in IL-1 
ra treated and vehicle control mice infected with 5x106 pfu HSV -1 RE. 
IL-1 Ra Tg mice show minimum angiogenic sprouts near the limbal ring 
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Fig 4. Human recombinant Interleukin-l ~eceptor antagonist protein was 
detected in mice receiving a combination of systemic and local 
administration till day 7post injection. 
At indicated time points, 6 corneas / group were processed for measuring 

the human recombinant IL-I ra protein levels. Level of human 

recombinant IL-I ra was estimated from supernatants of corneal lysates 

of mice infected with 5xI06 pfu HSV-I RE by an antibody capture 

ELISA as outlined in materials and methods. Results are expressed as 





Fig 5. Mice receiving IL-Z ra systemically in conjunction with local 
administration demonstrated reduced HSK severity. 
A. Interleukin-l receptor antagonist protein was administered 
systemically along with subconjunctival injection 24 hr before corneal 
infection as described in Materials and Methods. Mean lesion HSK score 
at day 20 p. i. of mice infected with Sxl06 pfu HSV-l RE. Each dot 
represents the HSK score from one eye. Horizontal bars and figures in 
the parenthesis indicate the Mean ± SD for each group. Data is compiled 
from two separate experiments consisting of 8 eyes in each group. *,** 
Statistically significant differences in mean HSK score (p< O.OS) were 
observed between mice treated with either Smglkg body wt. !hr for 7 days 
Sic + Imglcornea local (Group 1) or 2.5mgl kg body wt. Ihr for 7days 
Sic + Imglcornea local IL-l ra and vehicle control. 
B. Percentage severity of HSK score at day 20 p. i. of mice infected with 
Sxl06 pfu HSV-l RE. Each vertical bar represents number of eyes 
showing clinically evident lesions (HSK score~ 3). Data is compiled 
from two separate experiments consisting of 8 eyes in each group. 
C. Mice were infected with Sxl06 pfu HSV-l RE. Mice were terminated 
at day 20 p. i. and eyes were processed for paraffin embedding. 
Hematoxylin and Eosin staining was carried out on 6Jl sections. 
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Fig 6. Mice receiving a combination of systemic and local administration of 
IL-I ra protein showed diminished angiogenesis following ocular infection. 
A. Interleukin-l receptor antagonist protein was administered 
systemically along with subconjunctival injection 24 hr before corneal 
infection as described in Materials and Methods. Kinetics of corneal 
neovascularization process in mice infected with 5x106 pfu HSV-1 RE. 
Angiogenesis scores were recorded as mentioned in the Materials and 
Methods at indicated time points. Data is compiled from two separate 
experiments involving 8 eyes per group and is expressed as Mean ± SD.* 
Statistically significant differences in angiogenesis score (p< 0.05) were 
observed between mice treated with either 5mglkg body wt. Ihr for 7days 
SIc + Imglcornea local or 2.5mgl kg body wt. Ihr for 7days SIc + 
1mglcornea local IL-1 ra and vehicle control. 
B. Angiogenesis scores for individual eyes of IL-l ra treated, vehicle 
control and IL-1 ra Tg mice infected with 5x10?pfu HSV-1 RE at day 20 
p. i. Horizontal bars and figures show the mean for each group. Data are 
compiled from two separate experiments 
C. At day 20 p. i. extensive growth of blood vessels can be seen in IL-1 
ra treated and vehicle control mice infected with 5x106 pfu HSV -1 RE. 
IL-1 ra treated mice show minimum angiogenic sprouts near the limbal 
ring. In comparison, vehicle control eyes demonstrated extensive growth 
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Fig 7. Presence of abundant Gr-l+ve cells in the cornea of vehicle control 
mice but not in IL-l ra treated mice at 48 hr p. i. 
Single cell suspensions of corneal cells were prepared from 4 eyes at 48 
hr p. i. The cells were counted and stained with FITC labeled anti Gr-l 
antibody .and numbers of Gr-l positive cells were enumerated by FACS. 
Dotplot is representative of one of three separate experiments. The 
number on the upper right corner represents the percentage of Gr-l + cells 
of total corneal cells at 48 hr. p. i. 
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Fig 8. Diminished CD.r T cell influx in mice treated with IL-l ra protein. 
A. Single cell suspensions of corneal cells were prepared from 4 eyes at 
day 20 p. i. The cells were counted and stained with FITC labeled anti 
CD4+ antibody and numbers of positive cells were enumerated by FACS. 
Isotype control was used as negative control. Dot plot is the 
representative of one of three separate experiments. Numbers on the 
upper right comer represents the percentage of CD4+ T cells of total 
gated lymphocytes at day 20 p. i.. 
B. At day 20 p. i., representative eyes were taken and snap frozen in 
OCT compound and 6J.l sections were cut. The sections were stained for 
CD4+T cells using an FITC labeled anti CD4+antibody as described in 
Materials and Methods. Corneas were mounted with Vectashield 
mounting medium for fluorescence with Propidium Iodide and 
visualized under a microscope. The white arrows indicate the CD4+ T 
cells in the corneas. 
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Fig 9. IL-1 ra treated mice demonstrated reduced protein levels of IL-6, 
MIP-2 and VEGF. 
A, B & C. At indicated time points, 6 corneas /group were processed for 
measuring the IL-6, MIP-2 and VEGF protein levels. Levels of IL-6, 
MIP-2 and VEGF was estimated from supernatants of corneallysates of 
mice infected with 5xl06 pfu HSV-l RE by an antibody capture ELISA 
as outlined in materials and methods. Results are expressed as Mean ± 
SD of three separate experiments (6 corneas/time point). ·Statistically 
significant differences in IL-6, MIP-2 and VEGF level (p< 0.05) were 
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PART VI 

A NOVEL FLOW CYTOMETRY BASED 

ASSAY FOR QUANTIFICATION OF 

CORNEAL ANGIOGENESIS IN THE MOUSE 









Research described in this chapter is a slightly modified version of an article 
published in 2005 in Experimental Eye Research by Partha Sarathi Biswas, 
Kaustuv Banerjee, Bumseok Kim, Jordan Smith and Barry T. Rouse. 
Biswas, P. S., K. Banerjee, B. Kim, J. Smith, and and B. T. Rouse. 2005. A 
novel flow cytometry based assay for quantification of corneal angiogenesis in 
mouse model of herpetic stromal keratitis. Exp. Eye Res. 80(1):73. Copyright 
2004. The American Association ofImmunologists, Inc. 
In this chapter "we" and "our" refers to co-authors and me. My contributions 
in the paper include (1) selection of the topic (2) data analysis and 
interpretation (3) planning experiments (4) compiling and interpretation of the 
literature (5) understanding how results fit with the literature (7) compilation 
of contributions into one paper (8) providing structure to the paper (9) making 
graphs, figures and tables (10) writing and editing. 
ABSTRACT 
In this study a novel flow cytometry based quantitative assay for measuring 
corneal angiogenesis is demonstrated. Corneas of Balb/c mice were lightly 
scarified and infected with 5xl05, 5xl04 and 5xl03 pfu HSV-l RE virus. 
Development of corneal angiogenesis was studied on day 15 post infection by 
direct visualization of infected cornea with a slit-lamp biomicroscope. 
Endothelial cells constituting the newly developed blood vessels in cornea 
were stained with murine anti CD31 antibody on frozen corneal sections and 
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corneal whole mounts at day 15 p. i. Total number of endothelial cells was 
quantified at day 15 post infection by flow cytometry. Mice infected with 
different doses of HSV-1 RE developed severe to mild corneal angiogenesis at 
day 15 p. i. Endothelial cells constituting the newly formed blood vessels 
expressed CD31 at day 15 post infection. Flow cytometry revealed that, the 
number of CD31 positive cells isolated from diseased corneas increased with 
the increase in Neovascularization index. The flow cytometry analysis used in 
this present study is a useful, accurate and cost effective method for 
quantifying corneal angiogenesis. 
INTRODUCTION 
Herpetic stromal keratitis (HSK) is an immunoinflammatory lesion in the 
corneal stroma that ensues from ocular infection with Herpes simplex virus 
(HSV) (1). Studies in murine models have revealed a complex pathogenesis, 
involving multiple molecular and cellular events (2). One of these is 
neovascularization of the normally avascular cornea. New blood vessels sprout 
from vessels at the corneal lilnbus within 24 h of HSV infection (3), and 
eventually extend to the central cornea within the next 10-15 days (3). Such 
angiogenesis impairs vision and appears necessary for the ingress of T cells 
responsible for orchestrating HSK (2). Measuring corneal angiogenesis is 
normally accomplished by direct visualization with a slit-lamp biomicroscope 
and recording the area occupied by new vessels (4). This technique is tedious 
and subject to error especially when performed on living animals. In addition 
the approach fails to account for any difference in the vessel thickness. Other 
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techniques, including ultrasound micro-imaging and other microimaging 
technologies (5, 6) for angiogenesis quantification have been used but these 
require sophisticated instrumentation and trained personnel. 
In this report, an alternative approach for the quantification of corneal 
angiogenesis using a flow cytometry based assay is presented. Our results 
indicate that, following HSV infection endothelial cells constituting the newly 
formed blood vessels in corneal stroma express CD31 (PECAM 1). By 
targeting this surface marker by a fluorescently labeled antibody, number of 
endothelial cells in inflamed murine cornea could be quantified. The numbers 
of CD31 + cells were proportional to the growth of blood vessels in the infected 
cornea, as measured by biomicroscopy. In addition, number of CD31+ 
cell/cornea correlated with the angiogenic score. The flow cytometry based 
assay efficiently discriminated the difference in angiogenic response between 
mice infected with different doses of virus. Thus, estimation of angiogenesis 
on the basis of number of endothelial cells proved to be a potential technique 
for the quantification of corneal neovascularization. 
MATERIALS AND METHODS 
Mice 
Wild type female 6 to 8 weeks old Balb/c mice were purchased from Harlan 
Sprague-Dawley (Indianapolis, Indiana). Animals were sex and age matched 
for all experiments. To prevent bacterial superinfections, all mice received 
prophylactic treatment with Sulphatrim pediatric suspension (Barre-National 
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Baltimore, MD). All experimental procedures were in complete agreement 
with the Association for Research in Vision and Ophthalmology (ARVO) 
resolution on the use of animals in research. 
Virus 
HSV-l RE (obtained from Dr. Robert Hendricks Laboratory, University of 
Pittsburgh School of Medicine) was used in the present study. The virus was 
propagated and titrated on monolayer of Vero cells (ATCC, Cat No. CCL81) 
using standard protocols (7). Infected Vero cells were harvested, titrated and 
stored in aliquots at _80 
0 
C until used. 
Corneal HSV -1 infection 
Corneal infections of all mice groups were conducted under deep anesthesia 
induced by intraperitoneal injection of Avertin (Sigma, St. Louis, MO). Mice 
were scarified on their corneas with a 27 -gauge needle and a 4JlI drop 
containing the required dose of virus (5x105, 5xl04 and 5xl03 pfu) was 
applied to the eye and gently massaged with the eyelids. 
Angiogenesis Scoring 
The eyes were examined on day 15 post infection by a slit-lamp 
biomicroscope (Kowa Co. Nagoya, Japan) and angiogenesis severity was 
measured as described previously (4). Briefly, a grade of 4 for a given 
quadrant of the circle represents a centripetal growth of 1.5mm toward the 
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corneal center. The score of the 4 quadrants of the eye were then summed to 
derive the Neovascularization (NV) index (range 0-16) for each eye. 
Confocal Microscopy 
For immunohistochemistry, at day 15 p. i. eyes were frozen in optimum 
cutting temperature (OCT) compound (Miles, Elkart, IN). Six-micron-thick 
sections were cut, air dried, and fixed in cold acetone for 10 min at _200 C. 
The sections were blocked with 3% BSA (Sigma) containing unconjugated 
anti-CDI6/32 (1:200) antibody (Pharmingen, San Diego, CA) for 2 hour at 
37 0 C. For detection of endothelial cells in the stroma, the sections were 
incubated with FITC-coupled monoclonal anti-mouse CD31 antibody (anti 
mouse PECAMl) (Clone MECI3.3, Pharmingen) at a concentration of 1:500 
in 1 % BSA at 4°C overnight. Corneas were repeatedly washed in PBS and 
then mounted with Vectashield mounting medium for fluorescence with 
Propidium Iodide (Vector Laboratories Inc, Burlingame, CA) and visualized 
with a confocal microscope (Leica, Wetzlar, Germany). 
Immunofluorescence staining of blood vessels on corneal whole mounts 
Immunohistochemical staining for vascular endothelial cells was also 
performed on corneal flatmounts. At day 15 p. i. corneas from infected mice 
were dissected under stereo-microscope (Leica, Wetzlar, Germany). Then 
corneal wholemounts were rinsed in PBS for 30 minutes and flattened on a 
glass slide under stereo-microscope (Leica, Wetzlar, Germeny). Corneal 
flatmounts were dried and fixed in 100% acetone (Sigma, St. Louis, MO) for 
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10 minutes at -200 C. Nonspecific binding was blocked with 5% BSA (Sigma) 
containing unconjugated anti-CDI6/32 (1:200) antibody (Pharmingen) for 2 
hour at 370 C. Incubation with FITC-coupled monoclonal anti-mouse CD31 
antibody (anti mouse PECAMl) (Clone MECI3.3, Pharrningen) at a 
40concentration of 1 :250 in 1 % BSA at C overnight was followed by 

subsequent washes in PBS at room temperature. Corneas were mounted with 

Vectashield mounting medium for fluorescence with Propidium Iodide 

(Vector Laboratories Inc, Burlingame, CA) and visualized with a fluorescence 





Mice were infected with different doses of HSV-l RE. At day 15 p. i., 

N eovascularization index of individual eyes were determined by direct 

visualization of infected corneas with slit-lamp biomicroscope. Two corneas 

with similar NV index were pooled together and stained for number of CD31+ 

cells/cornea. This was repeated three times. 

In another set of experiments, three groups of mice were infected with 
5xl05, 5xl04 and 5xl03 pfu HSV-l RE. At day 15 p. L, NV index of 
individual eyes were determined by direct visualization of infected corneas 
with slit-lamp biomicroscope. Two corneas with a NV index and closest to the 
Mean NV index of that group were pooled together and stained for number of 
CD31+ cells/cornea. This experiment was repeated thrice. 
Staining procedure: Corneas were dissected carefully under a stereo­
microscope (Leica, Wetzlar, Germany). All precautions were taken to avoid 
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the limbal blood vessels. Single-cell suspensions were prepared from 2 

corneas at day 15 post infection as described elsewhere (8), with some 

modifications. Briefly, corneal buttons were incubated with collagenase D 

(Roche) for 60 min at 37°C in a humidified atmosphere at 5% C02. After 

incubation, corneas were disrupted by grinding with a syringe plunger and 

passing through a cell strainer. Cells were washed and suspended in RPMI 

1640 with 10% FBS and counted by Trypan Blue staining. The Fe receptors on 

the cells were blocked with unconjugated anti-CD 16/32 (Pharmingen) for 30 

min. Samples were incubated with FITC labeled anti CD31 antibody (Clone 

MECI3.3, Pharmingen) and isotype controls for 30 minutes. All samples were 

collected on a FACScan (BD Biosciences, San Diego, CA), and data were 





Data obtained were analyzed for statistical significance by Student's t test. 






Endothelial cells constituting the newly developed blood vessels express 
CD31 (PECAM 1) following corneal HSV-1 infection. 
Endothelial cells making up the newly formed blood vessels are characterized 
by the expression of adhesion molecules such as CD31 (PECAM 1), Vascular 
endothelial - cadherin (VE-cad) and von Willebrand factor (9). Expression of 
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these surface molecules on endothelial cells are regulated by inflammatory 
mediators (10, 11). To find out whether endothelial cells constituting the 
newly developed blood vessels express CD31, corneas of infected mice were 
stained for CD31. As demonstrated in Fig. 1 A, endothelial cells making up the 
newly grown blood vessels in corneal stroma expressed CD31 (PECAM 1) at 
day 15 p. i. In addition, fluorescently labeled anti CD31 antibody stained the 
blood vessels on corneal whole mounts at the same time point (Fig. IB). Thus, 
targeting CD31 with a fluorescently coupled antibody may prove to be a 
reliable and efficient tool to label and quantify the number of endothelial cells 
in corneal angiogenesis. 
Increase in the number of CD31+ cells is associated with the increase in 
Neovascularization (NV) index 
At day 15 p. i., the NV index of individual eyes was determined by slit-lamp 
biomicroscopy. Two corneas with similar NV index were pooled together and 
the nUlnber of CD31 + cells was counted by FACS analysis. As demonstrated 
in Fig 2A, 2B and 2C, corneas with higher NV index have more CD31 + 
cells/cornea. In contrast to naIve cornea, there was a gradual increase in the 
number of CD31 + cells/cornea with the increase in NV index. In addition, a 
strong correlation (r = 0.965, p~ 0.0002) was observed between NV index and 
number of CD31 + cells/cornea. Isotype control showed no background 
staining. Greater than 65% of mouse brain endothelial cells (positive control) 
stained positive for CD31 (data not shown). Overall, this experiment revealed 





visualization of infected cornea at day 15 p. L 
Difference in the number of CD31+ cells/cornea in mice infected with 
different doses of virus 
Three groups of mice were infected with 5xl05 pfu, 5xl04 pfu and 5xl03 pfu 
HSV-l RE respectively. At day 15 p. L, the NV index of individual eyes was 
scored by slit-lamp biomicroscopy. As shown in Fig. 3, groups of mice 
infected with 5xl05 pfu, 5xl04 pfu and 5xl03 pfu HSV-l RE had mean NV 
index of 10.7, 5.6 and 1.8 respectively. Mean NV index of mice infected with 
5xl05 pfu was significantly (p< 0.05) higher than mean NV index of mice 
infected with 5xl04 and 5xl03 pfu virus. Two eyes from each group with NV 
indexes close to the group mean were pooled together and number of CD31 + 
cells/cornea were quantified using flow cytometry. Once again there was a 
concordance between the two assays. Group infected with the highest dose 
(5xl05 pfu) and showing higher mean NV index h~ve significantly (p< 0.05) 
greater number of CD31 + cells/cornea (18,365 ±3499) in comparison to 5xl04 
pfu (925 ± 478) and 5xl03 pfu (130 ± 61) (Fig. 4A, B and C). Thus in 
comparison with the average number of endothelial cells/cornea, mice infected 
with 5xl05 pfu have approximately 20 fold (5xl04 pfu) and 200 fold (5xl03 
pfu) more CD31 + cells/cornea. 
DISCUSSION 
In this study a novel flow cytometry based assay was used to quantify corneal 
angiogenesis following ocular HSV infection. Our results indicate that, 
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endothelial cells constituting the newly fonned blood vessels in corneal stroma 
express CD31 (PECAM 1) at day 15 post infection. Thus, labeling the blood 
vessel endothelial cells by targeting this surface marker provided a unique 
opportunity to quantify the number of endothelial cells/cornea. The data 
revealed that, the number of CD31 + cells/cornea was proportional to the 
growth of blood vessels in infected cornea. In addition, this assay was able to 
pick up the difference in angiogenic response between mice infected with 
different doses of virus. Thus, estimation of angiogenesis on the basis of 
number of endothelial cells proved to be a useful approach to quantify corneal 
neovascularization. 
Strongly woven endothelial cells on cellular matrix make up the wall 
for blood vessels. With the increase in length, thickness and number of 
vasculature, increase in the number of endothelial cells constituting the newly 
developed vessels were expected. Thus, quantifying the number of endothelial 
cells would directly reflect the amount of blood vessels present in the corneal 
tissue at a particular time point. By the virtue of this assay, we were able to 
consider the three-dimensional structure i.e. length, width and height of a 
blood vessel instead of relying on the visualization of surface vasculature 
during the process of quantification by conventional way. 
As evident from our study, the cell-based assay was responsive enough 
to detect the gradual increase in the number of endothelial cells with the 
increase in NV index. To our knowledge, this is the first report where the 
growth of blood vessels has been successfully represented by a cell-based 
assay. In addition, this assay was able to differentiate the angiogenic response 
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observed following infection with various doses of virus. However, the flow 
cytometry based assay for quantification of corneal angiogenesis has some 
shortcomings. These include the fact that, this is a terminal assay and cannot 
be used for angiogenesis kinetics study. Besides this, in case of naIve mice, in 
spite of an absence of an angiogenic score, still approximately 0.1 % of cells 
were CD31 +. We believe that this discordance was attributed to the underlined 
corneal endothelium layer. Adding up, was the possibility of overestimation 
due to possible contamination of limbal blood vessel endothelial cells. 
Currently we are in the process of overcoming these constraints to make it 
more accurate and reliable. 
In this report, we demonstrated an alternative approach of 
quantification of corneal angiogenesis in mouse model of HSK. The cell based 
technique closely resembled the commonly used method to quantify corneal 
angiogenesis. It would be of particular interest to know whether this flow 
cytometry technique is useful in assessing angiogenesis in other corneal 
inflammatory models and tumor systems. Overall, estimation of angiogenesis 
on the basis of number of endothelial cells may be a potential technique for the 




SlI:JNlIHlIdllH dO ~S17 
LIST OF REFERENCES 
1. 	 Streilein, 1. W., M. R. Dana, and B. R. Ksander. 1997. Immunity 
causing blindness: five different paths to herpes stromal keratitis. 
Immunol Today 18:443. 
2. 	 Deshpande, S., K. Banerjee, P. S. Biswas, and B. T. Rouse. 2004. 
Herpetic eye disease: immunopathogenesis and therapeutic measures. 
Expert Rev Mol Med 2004: 1. 
3. 	 Zheng, M., M. A. Schwarz, S. Lee, U. Kumaraguru, and B. T. Rouse. 
2001. Control of stromal keratitis by inhibition of neovascularization. 
Am J PathoI159:1021. 
4. 	 Dana, M. R., S. N. Zhu, and J. Yamada. 1998. Topical modulation of 
interleukin-1 activity in corneal neovascularization. Cornea 17:403. 
5. 	 Strohmeyer, D., F. Frau scher, A. Klauser, W. Recheis, G. Eibl, W. 
Horninger, H. Steiner, H. Volgger, and G. Bartsch. 2001. Contrast­
enhanced transrectal color doppler ultrasonography (TRCDUS) for 
assessment of angiogenesis in prostate cancer. Anticancer Res 
21:2907. 
6. 	 Hoffman, R. 2002. Green fluorescent protein imaging of tumour 
growth, metastasis, and angiogenesis in mouse models. Lancet Oncol 
3:546. 
7. 	 Spear, P. G., and B. Roizman. 1972. Proteins specified by herpes 
simplex virus. V. Purification and structural proteins of the 
herpesvirion. J ViroI9:143. 
228 

8. Deshpande, S., M. Zheng, S. Lee, K. Banerjee, S. Gangappa, U. 
Kumaraguru, and B. T. Rouse. 2001. Bystander activation involving T 
lymphocytes in herpetic stromal keratitis. J Immunol 167:2902. 
9. 	 Hristov, M., W. Erl, and P. C. Weber. 2003. Endothelial progenitor 
cells: mobilization, differentiation, and homing. Arterioscler Thromb 
Vase Bioi 23:1 185. 
10. 	 Pober, J. S. 1987. Effects of tumour necrosis factor and related 
cytokines on vascular endothelial cells. Ciba Found Symp 131:170. 
11. 	 Vorkauf, W., M. Vorkauf, B. Nolle, and G. Duncker. 1995. Adhesion 
molecules in normal and pathological corneas. An 
immunohistochemical study using monoclonal antibodies. Graefes 









Fig 1. Endothelial cells constituting the new blood vessels in corneal stroma 
express CD31 at day 15 post infection. 
A. At day 15 p. i. eyes were frozen in OCT compound and six micron 
sections were made. The slides were stained with monoclonal anti mouse 
CD31 primary antibody and biotinylated anti rat IgG secondary 
antibody. Diaminobenzidine was used as substrate, and sections were 
counterstained with hematoxylin. Original magnification x200. The 
black arrow (inset) indicates the cross section of endothelial cells lining 
the lumen of a blood vessel in the corneal stroma. 
B. At day 15 p. i. eyes were frozen in OCT compound and six micron 
sections were made. The slides were stained with FITC-coupled 
monoclonal anti mouse CD31 antibody. The slides were counterstained 
with Propidium Iodide and visualized under a Leica SP2 Laser scanning 
confocal microscope (Leica, Wetzlar, Germany). The white arrow (inset) 
indicates the cross section of endothelial cells lining the lumen of a 
blood vessel in the corneal stroma. 
C. Immunohistochemical staining for vascular endothelial cells was 
performed on corneal flatmounts at day 15 post infections with FITC­
coupled monoclonal anti-mouse CD31 antibody. Corneas were mounted 
with an anti fading agent containing Propidium Iodide and visualized 
with a Leica SP2 Laser scanning confocal microscope (Leica, Wetzlar, 
Germany). Extensive neovascularization was observed from limbal 
blood vessels at day 15 post infection. NaIve mice showed little or no 
angiogenic sprouts near the limbal ring. The solid and double white 
231 

arrows indicate the limbal blood vessel and newly grown blood vessel in 
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Fig 2. Increase in the number of CD31+ cells is associated with heightened 
angiogenic response following corneal micropocket assay. 
Hydron pellets (black arrow) containing VEGF (200 ng) were implanted 
into the corneal pockets (n=6). Control mice received pellets only. At 
day 4 post implantation angiogenic response was assessed. Two corneas 
demonstrating similar angiogenic response were pooled together and 
number of CD31+ cells was enumerated by FACS analysis as described 
in Materials and Methods. The dot plot represents one of the three 
separate experiments. The number in the right hand comer represents 
percentage of CD31+ cells. 
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Fig 3. Increase in the number of CD31+ cells is associated with the increase 
in NV index at day 15 p. i. 
A. Mice were infected with different doses of HSV-l RE (5xl05 pfu, 
5xl04 pfu and 5xl03 pfu). Individual eyes were scored for angiogenesis 
(NV index) with slit lamp bio-microscope at day 15 p. i. Two corneas of 
same NV index were pooled together and stained with FITC labeled 
CD31+ antibody. A total volume of 100)l1 cell suspension containing 5xl04 
cells was spinned down. The slides were counterstained with Propidium 
Iodide and visualized under a microscope (Leica, Wetzlar, Germany). 
Original magnification x200 
B. Mice were infected with different doses of HSV-1 RE (5xl05 pfu, 5xl04 
pfu and 5xl03 pfu). Individual eyes were scored for angiogenesis (NV 
index) with slit lamp bio-microscope at day 15 p. i. Two corneas of same 
NV index were pooled together and number of CD31 + cells was 
enumerated by FACS analysis as described in Materials and Methods. The 
dot plot represents one of the three separate experiments. The number in 
the right hand comer represents percentage of CD31 + cells. 
C. Blood vessel development of representative eyes with various NV 
index. Photographs were taken at day 15 p. i. before FACS analysis. 
Representative eyes with NV index of 14 demonstrated extensive blood 
vessel development, whereas eyes with NV index of 2 show minimal 
blood vessel development. 
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D. The line diagram represents a steady increase in the number of CD31 + 
cells/cornea with the increase in NV index. The data is accumulated from 
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Fig 4. Mice infected with higher dose of virus demonstrated increased 
number ofCD31+ cells/cornea at day 15 p. i. 
A. Three groups of mice (n = 8) were infected with 5xl05 pfu, 5xl04 pfu 
and 5xl03 pfu of HSV-l RE respectively. Individual eyes were scored 
(NV index) for angiogenic response at day 15 p. i. with a slit lamp 
biomicroscope. Two corneas/group having a NV index closest to the 
mean NY index of that group were pooled together and number of 
CD31+ cells was enumerated by FACS analysis as described in Materials 
and Methods. The dot plot represents one of the three separate 
experiments. The number in the right hand comer represents percentage 
of CD31+ cells. 
B. Blood vessel development of representative eyes with various NV 
index. Photographs were taken at day 15 p. i. before FACS analysis. 
Representative eyes from different groups showing variable degree of 
angiogenic response at day 15 p. i. 
C. The bar diagram represents the number of CD31 + cells/ cornea at day 
15 p. i. Figure in the parenthesis indicate the Mean NV index for each 
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